



US 20190067599A1

(19) **United States**(12) **Patent Application Publication**
KRAVCHUK et al.(10) **Pub. No.: US 2019/0067599 A1**(43) **Pub. Date: Feb. 28, 2019**(54) **ORGANOMETALLIC COMPOUND AND
ORGANIC LIGHT-EMITTING DEVICE
INCLUDING THE SAME**(71) Applicants: **Samsung Electronics Co., Ltd.**,
Suwon-si (KR); **Samsung SDI Co.,
Ltd.**, Suwon-si (KR)(72) Inventors: **Dmitry KRAVCHUK**, Hwaseong-si
(KR); **Wook KIM**, Suwon-si (KR);
Juhyun KIM, Suwon-si (KR);
Changho NOH, Suwon-si (KR);
Sangho PARK, Anyang-si (KR);
Satoko ISHIBE, Seongnam-si (KR);
Seokho KANG, Seoul (KR); **Inkoo
KIM**, Suwon-si (KR); **Jiho YOO**,
Hwaseong-si (KR); **Dongseon LEE**,
Suwon-si (KR); **Hasup LEE**, Seoul
(KR); **Jun CHWAE**, Seoul (KR)(21) Appl. No.: **16/057,929**(22) Filed: **Aug. 8, 2018**(30) **Foreign Application Priority Data**

Aug. 31, 2017 (KR) 10-2017-0111043

Publication Classification(51) **Int. Cl.****H01L 51/00** (2006.01)**C07F 15/00** (2006.01)(52) **U.S. Cl.**CPC **H01L 51/0085** (2013.01); **H01L 51/5016**
(2013.01); **C07F 15/0033** (2013.01)

(57)

ABSTRACT

An organometallic compound represented by Formula 1:

Formula 1



wherein, in Formula 1, groups and variables are the same
as described in the specification.

FIG. 1




FIG. 2




FIG. 3





FIG. 4



ORGANOMETALLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME

CROSS-REFERENCE TO RELATED APPLICATION

[0001] This application claims priority to Korean Patent Application No. 10-2017-0111043, filed on Aug. 31, 2017, in the Korean Intellectual Property Office, and all the benefits accruing therefrom under 35 U.S.C. § 119, the content of which is incorporated herein in its entirety by reference.

BACKGROUND

1. Field

[0002] One or more embodiments relate to an organometallic compound and an organic light-emitting device including the same.

2. Description of the Related Art

[0003] Organic light-emitting devices (OLEDs) are self-emission devices that produce full-color images, and that also have wide viewing angles, high contrast ratios, short response times, and excellent characteristics in terms of brightness, driving voltage, and response speed, compared to devices in the art.

[0004] In an example, an organic light-emitting device includes an anode, a cathode, and an organic layer disposed between the anode and the cathode, wherein the organic layer includes an emission layer. A hole transport region may be disposed between the anode and the emission layer, and an electron transport region may be disposed between the emission layer and the cathode. Holes provided from the anode may move toward the emission layer through the hole transport region, and electrons provided from the cathode may move toward the emission layer through the electron transport region. The holes and the electrons recombine in the emission layer to produce excitons. These excitons transit from an excited state to a ground state, thereby generating light.

[0005] Various types of organic light emitting devices are known. However, there still remains a need in OLEDs having low driving voltage, high efficiency, high brightness, and long lifespan.


SUMMARY

[0006] Aspects of the present disclosure provide a novel organometallic compound and an organic light-emitting device including the same.

[0007] Additional aspects will be set forth in part in the description which follows and, in part, will be apparent from the description, or may be learned by practice of the presented embodiments.

[0008] An aspect provides an organometallic compound represented by Formula 1:

Formula 1



[0009] in Formula 1,

[0010] M_{11} is selected from first-row transition metals, second-row transition metals, third-row transition metals, first-row post-transition metals, second-row post-transition metals, and third-row post-transition metals,

[0011] A_{11} and A_{12} are each independently a nitrogen atom-containing C_1 - C_{30} heterocyclic group,

[0012] X_{11} and X_{12} are each independently selected from C and N,

[0013] X_{13} is C,

[0014] R_{11} to R_{13} are each independently selected from hydrogen, deuterium, $-F$, $-Cl$, $-Br$, $-I$, $-SF_5$, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a substituted or unsubstituted C_1 - C_{60} alkyl group, a substituted or unsubstituted C_2 - C_{60} alkenyl group, a substituted or unsubstituted C_2 - C_{60} alkynyl group, a substituted or unsubstituted C_1 - C_{60} alkoxy group, a substituted or unsubstituted C_3 - C_{10} cycloalkyl group, a substituted or unsubstituted C_1 - C_{10} heterocycloalkyl group, a substituted or unsubstituted C_3 - C_{10} cycloalkenyl group, a substituted or unsubstituted C_1 - C_{10} heterocycloalkenyl group, a substituted or unsubstituted C_6 - C_{60} aryl group, a substituted or unsubstituted C_6 - C_{60} aryloxy group, a substituted or unsubstituted C_6 - C_{60} arylthio group, a substituted or unsubstituted C_1 - C_{60} heteroaryl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group, $-N(Q_1)(Q_2)$, $-Si(Q_3)(Q_4)(Q_5)$, $-B(Q_6)(Q_7)$, and $-P(=O)(Q_8)(Q_9)$,

[0015] R_{11} to R_{13} are optionally linked to form a ring,

[0016] two, three, or four of a plurality of R_{11} to R_{13} that are adjacent to each other are optionally linked to form a quadridentate, hexadentate, or octadentate ligand,

[0017] b_{12} and b_{13} are each independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10,

[0018] n_{11} is selected from 1, 2, 3, and 4,

[0019] n_{12} is selected from 0, 1, 2, and 3,

[0020] L_{12} is selected from a bidentate ligand, and

[0021] Q_1 to Q_9 are each independently selected from hydrogen, deuterium, $-F$, $-Cl$, $-Br$, $-I$, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C_1 - C_{60} alkyl group, a C_1 - C_{60} alkyl group substituted with at least one selected

from deuterium, a C₁-C₆₀ alkyl group, and a C₆-C₆₀ aryl group, a C₂-C₆₀ alkenyl group, a C₂-C₆₀ alkynyl group, a C₁-C₆₀ alkoxy group, a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₆-C₆₀ aryl group substituted with at least one selected from deuterium, a C₁-C₆₀ alkyl group, and a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₁-C₆₀ heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group.

[0022] Another aspect provides an organic light-emitting device including:

[0023] a first electrode;

[0024] a second electrode; and

[0025] an organic layer disposed between the first electrode and the second electrode,

[0026] wherein the organic layer includes an emission layer, and

[0027] wherein the organic layer includes the organometallic compound. The organometallic compounds may act as a dopant in the emission layer.

BRIEF DESCRIPTION OF THE DRAWING

[0028] These and/or other aspects will become apparent and more readily appreciated from the following description of the embodiments, taken in conjunction with the accompanying drawings in which:

[0029] FIG. 1 is a schematic view of an organic light-emitting device according to an embodiment;

[0030] FIG. 2 is a graph of intensity (arbitrary unit, a. u.) versus mass-to-charge ratio (m/z) that shows data resulted from matrix-assisted laser desorption/ionization (MALDI) with respect to Compound 8;

[0031] FIG. 3 is a graph of intensity versus chemical shift (part per million, ppm) that shows data resulted from ¹H-NMR with respect to Compound 8; and

[0032] FIG. 4 is a graph of intensity (arbitrary unit, a. u.) versus wavelength (nanometers, nm) that shows photoluminescence (PL) spectrum data of Compound 8.

DETAILED DESCRIPTION

[0033] Reference will now be made in detail to embodiments, examples of which are illustrated in the accompanying drawings, wherein like reference numerals refer to like elements throughout. In this regard, the present embodiments may have different forms and should not be construed as being limited to the descriptions set forth herein. Accordingly, the embodiments are merely described below, by referring to the figures, to explain aspects of the present description. As used herein, the term “and/or” includes any and all combinations of one or more of the associated listed items. Expressions such as “at least one of,” when preceding a list of elements, modify the entire list of elements and do not modify the individual elements of the list.

[0034] It will be understood that when an element is referred to as being “on” another element, it can be directly in contact with the other element or intervening elements may be present therebetween. In contrast, when an element is referred to as being “directly on” another element, there are no intervening elements present.

[0035] It will be understood that, although the terms first, second, third etc. may be used herein to describe various

elements, components, regions, layers, and/or sections, these elements, components, regions, layers, and/or sections should not be limited by these terms. These terms are only used to distinguish one element, component, region, layer, or section from another element, component, region, layer, or section. Thus, a first element, component, region, layer, or section discussed below could be termed a second element, component, region, layer, or section without departing from the teachings of the present embodiments.

[0036] The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting. As used herein, the singular forms “a,” “an,” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise.

[0037] The term “or” means “and/or.” It will be further understood that the terms “comprises” and/or “comprising,” or “includes” and/or “including” when used in this specification, specify the presence of stated features, regions, integers, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, regions, integers, steps, operations, elements, components, and/or groups thereof.


[0038] Unless otherwise defined, all terms (including technical and scientific terms) used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this general inventive concept belongs. It will be further understood that terms, such as those defined in commonly used dictionaries, should be interpreted as having a meaning that is consistent with their meaning in the context of the relevant art and the present disclosure, and will not be interpreted in an idealized or overly formal sense unless expressly so defined herein.

[0039] Exemplary embodiments are described herein with reference to cross section illustrations that are schematic illustrations of idealized embodiments. As such, variations from the shapes of the illustrations as a result, for example, of manufacturing techniques and/or tolerances, are to be expected. Thus, embodiments described herein should not be construed as limited to the particular shapes of regions as illustrated herein but are to include deviations in shapes that result, for example, from manufacturing. For example, a region illustrated or described as flat may, typically, have rough and/or nonlinear features. Moreover, sharp angles that are illustrated may be rounded. Thus, the regions illustrated in the figures are schematic in nature and their shapes are not intended to illustrate the precise shape of a region and are not intended to limit the scope of the present claims.

[0040] “About” or “approximately” as used herein is inclusive of the stated value and means within an acceptable range of deviation for the particular value as determined by one of ordinary skill in the art, considering the measurement in question and the error associated with measurement of the particular quantity (i.e., the limitations of the measurement system). For example, “about” can mean within one or more standard deviations, or within ±30%, 20%, 10%, 5% of the stated value.

[0041] In an embodiment, an organometallic compound represented by Formula 1 is provided:

Formula 1



[0042] In Formula 1, M_{11} may be selected from first-row transition metals, second-row transition metals, third-row transition metals, first-row post-transition metals, second-row post-transition metals, and third-row post-transition metals.

[0043] For example, in Formula 1, M_{11} may be selected from platinum (Pt), palladium (Pd), copper (Cu), silver (Ag), gold (Au), rhodium (Rh), iridium (Ir), ruthenium (Ru), osmium (Os), titanium (Ti), zirconium (Zr), hafnium (Hf), rhenium (Re), europium (Eu), terbium (Tb), thulium (Tm), and lead (Pb), but embodiments of the present disclosure are not limited thereto.

[0044] In one or more embodiments, in Formula 1, M_{11} may be selected from Pt, Pd, Ir, Ru, Os, Re, and Pb, but embodiments of the present disclosure are not limited thereto.

[0045] In one or more embodiments, in Formula 1, M_{11} may be selected from Ir, Os, and Pt, but embodiments of the present disclosure are not limited thereto.

[0046] In one or more embodiments, in Formula 1, M_{11} may be Ir, but embodiments of the present disclosure are not limited thereto.

[0047] In Formula 1, A_{11} and A_{12} may each independently be selected from a nitrogen atom-containing C_1 - C_{30} heterocyclic group.

[0048] For example, in Formula 1, A_{11} and A_{12} may each independently be selected from an indole group, a carbazole group, an indenopyridine group, an indolopyridine group, a benzofuopyridine group, a benzothienopyridine group, a benzosilolopyridine group, an indenopyrimidine group, an indolopyrimidine group, a benzofuopyrimidine group, a benzothienopyrimidine group, a dihydropyridine group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, a quinoline group, an isoquinoline group, a quinoxaline group, a quinazoline group, a phenanthroline group, a pyrrole group, a pyrazole group, an imidazole group, a 2,3-dihydroimidazole group, a triazole group, a 2,3-dihydrotriazole group, an oxazole group, an isoxazole group, a thiazole group, an isothiazole group, an oxadiazole group, a thiadiazole group, a benzopyrazole group, a benzimidazole group, a 2,3-dihydrobenzimidazole group, an imidazopyridine group, a 2,3-dihydroimidazopyridine group, an imidazopyrimidine group, a 2,3-dihydroimidazopyrimidine group, an imidazopyrazine group, a 2,3-dihydroimidazopyrazine group, a benzoxazole group, a benzothiazole group, a benzooxadiazole group, a benzothiadiazole group, a 5,6,7,

8-tetrahydroisoquinoline group, and a 5,6,7,8-tetrahydroquinoline group, but embodiments of the present disclosure are not limited thereto.


[0049] In one or more embodiments, in Formula 1, A_{11} and A_{12} may each independently be selected from an indenopyridine group, an indolopyridine group, a benzofuopyridine group, a benzothienopyridine group, a benzosilolopyridine group, an indenopyrimidine group, an indolopyrimidine group, a benzofuopyrimidine group, a benzothienopyrimidine group, a benzosilolo-pyrimidine group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, a quinoline group, an isoquinoline group, a quinoxaline group, a quinazoline group, a phenanthroline group, an imidazopyridine group, an imidazopyrimidine group, and an imidazopyrazine group, but embodiments of the present disclosure are not limited thereto.

[0050] In one or more embodiments, in Formula 1, A_{11} and A_{12} may each independently be selected from a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, a quinoline group, an isoquinoline group, a quinoxaline group, a quinazoline group, and a phenanthroline group, but embodiments of the present disclosure are not limited thereto.


[0051] In Formula 1, X_{11} and X_{12} may each independently be selected from C and N.

[0052] For example, in Formula 1, X_{11} and X_{12} may each independently be C, but embodiments of the present disclosure are not limited thereto.


[0053] In one or more embodiments, in Formula 1, a partial structure represented by



(wherein * and *' each indicate a binding site to a neighboring atom) may be represented by one of Formulae 2-1 to 2-12, but embodiments of the present disclosure are not limited thereto:




2-1




2-2


-continued




2-3




2-4




2-5




2-6



2-7




2-8




2-9


-continued



2-10



2-11



2-12


[0054] In Formulae 2-1 to 2-12,

[0055] R_{11} is the same as described in connection with Formula 1,

[0056] R_{21} to R_{24} may each independently be the same as described in connection with R_{12} in Formula 1, and

[0057] * and *f each indicate a binding site to a neighboring atom.

[0058] In various embodiments, in Formula 1, a partial structure represented by




2-7

(wherein * and *f each indicate a binding site to a neighboring atom) may be represented by one of Formulae 2-1 to 2-4, but embodiments of the present disclosure are not limited thereto.

[0059] In Formula 1, X_{13} may be C.


[0060] In one or more embodiments, in, Formula 1, a moiety represented by



2-9

may be represented by one of Formulae 3-1 to 3-5, but embodiments of the present disclosure are not limited thereto.

[0061] In one or more embodiments, in Formula 1, a moiety represented by



may be represented by Formula 3-1, but embodiments of the present disclosure are not limited thereto.

[0062] In Formula 1, R_{11} to R_{13} may each independently be selected from hydrogen, deuterium, $-F$, $-Cl$, $-Br$, $-I$, $-SF_5$, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a substituted or unsubstituted C_1 - C_{60} alkyl group, a substituted or unsubstituted C_2 - C_{60} alkenyl group, a substituted or unsubstituted C_2 - C_{60} alkynyl group, a substituted or unsubstituted C_1 - C_{60} alkoxy group, a substituted or unsubstituted C_3 - C_{10} cycloalkyl group, a substituted or unsubstituted C_1 - C_{10} heterocycloalkyl group, a substituted or unsubstituted C_3 - C_{10} cycloalkenyl group, a substituted or unsubstituted C_1 - C_{10} heterocycloalkenyl group, a substituted or unsubstituted C_6 - C_{60} aryl group, a substituted or unsubstituted C_6 - C_{60} aryloxy group, a substituted or unsubstituted C_6 - C_{60} arylthio group, a substituted or unsubstituted C_1 - C_{60} heteroaryl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group, $-N(Q_1)(Q_2)$, $-Si(Q_3)(Q_4)(Q_5)$, $-B(Q_6)(Q_7)$, and $-P(=O)(Q_8)(Q_9)$.

[0063] R_{11} to R_{13} may optionally be linked to form a ring.

[0064] Q_1 to Q_9 may each independently be selected from hydrogen, deuterium, $-F$, $-Cl$, $-Br$, $-I$, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C_1 - C_{60} alkyl group, a C_1 - C_{60} alkyl group substituted with at least one selected from deuterium, a C_1 - C_{60} alkyl group, and a C_6 - C_{60} aryl group, a C_2 - C_{60} alkenyl group, a C_2 - C_{60} alkynyl group, a C_1 - C_{60} alkoxy group, a C_3 - C_{10} cycloalkyl group, a C_1 - C_{10} heterocycloalkyl group, a C_3 - C_{10} cycloalkenyl group, a C_1 - C_{10} heterocycloalkenyl group, a C_6 - C_{60} aryl group, a C_6 - C_{60} aryl group substituted with at least one selected from deuterium, a C_1 - C_{60} alkyl group, and a C_6 - C_{60} aryl group, a C_6 - C_{60} aryloxy group, a C_6 - C_{60} arylthio group, a C_1 - C_{60} heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group.

[0065] For example, in Formula 1, R_{11} to R_{13} may each independently be selected from:

[0066] hydrogen, deuterium, $-F$, $-Cl$, $-Br$, $-I$, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic

acid group or a salt thereof, a phosphoric acid group or a salt thereof, $-SF_5$, C_1 - C_{20} alkyl group, and a C_1 - C_{20} alkoxy group;

[0067] a C_1 - C_{20} alkyl group and a C_1 - C_{20} alkoxy group, each substituted with at least one selected from deuterium, $-F$, $-Cl$, $-Br$, $-I$, $-CD_3$, $-CD_2H$, $-CDH_2$, $-CF_3$, $-CF_2H$, $-CFH_2$, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C_1 - C_{10} alkyl group, a cyclopentyl group, a cyclopentyl group substituted with deuterium, a cyclohexyl group, a cyclohexyl group substituted with deuterium, a cycloheptyl group, a cycloheptyl group substituted with deuterium, a cyclooctyl group, a cyclooctyl group substituted with deuterium, a bicyclo[2.2.1]heptanyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a pyridinyl group, and a pyrimidinyl group;

[0068] a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, a bicyclo[2.2.1]heptanyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzimidazolyl group, a benzofuranyl group, a benzothienophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a dibenzosilolyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, and an imidazopyrimidinyl group;

[0069] a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, a bicyclo[2.2.1]heptanyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzimidazolyl group, a benzofuranyl group, a benzothienophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a


[0076] hydrogen, deuterium, —F, a cyano group, a nitro group, —SF₅, a methyl group, an ethyl group, an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl

[0081] an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl


group, an n-pentyl group, an isopentyl group, a sec-pentyl group, a tert-pentyl group, a phenyl group, and a naphthyl group; and






















[0082] an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, a sec-pentyl group, a tert-pentyl group, a phenyl group, and a naphthyl group, each substituted with at least one selected from deuterium, a C_1 - C_{10} alkyl group, and a phenyl group, but embodiments of the present disclosure are not limited thereto.

[0083] In one or more embodiments, in Formula 1, R_{11} to R_{13} may each independently be selected from hydrogen, deuterium, $-F$, a cyano group, a nitro group, $-SF_5$, $-CH_3$, $-CD_3$, $-CD_2H$, $-CDH_2$, $-CF_3$, $-CF_2H$, $-CFH_2$, groups represented by Formulae 9-1 to 9-21, groups represented by Formulae 10-1 to 10-253, $-N(Q_1)(Q_2)$, $-Si(Q_3)(Q_4)(Q_5)$, $-B(Q_6)(Q_7)$, and $-P(=O)(Q_8)(Q_9)$, but embodiments of the present disclosure are not limited thereto:




-continued




-continued		-continued	
	10-6		10-16
	10-7		10-17
	10-8		10-18
	10-9		10-19
	10-10		10-20
	10-11		10-21
	10-12		10-22
	10-13		10-23
	10-14		10-24
	10-15		10-25
			10-26


-continued




10-27




10-28




10-29




10-30




10-31




10-32




10-33




10-34



10-35




10-36




10-37


-continued




10-38




10-39




10-40




10-41




10-42




10-43




10-44




10-45




10-46




10-47




10-48
10-49
10-50
10-51
10-52
10-53
10-54
10-55
10-56
10-57
10-58



10-59
10-60
10-61
10-62
10-63
10-64
10-65
10-66
10-67
10-68
10-69




10-70
10-71
10-72
10-73
10-74
10-75
10-76
10-77
10-78
10-79




10-80
10-81
10-82
10-83
10-84
10-85
10-86
10-87
10-88
10-89
10-90


-continued




10-91




10-92




10-93




10-94




10-95




10-96



10-97




10-98




10-99


-continued




10-100




10-101




10-102




10-103




10-104




10-105



10-106




10-107




10-108


-continued




10-109




10-110




10-111




10-112




10-113



10-114




10-115




10-116


-continued




10-117




10-118




10-119




10-120




10-121




10-122



10-123




10-124




10-125


-continued




10-126




10-127




10-128




10-129




10-130




10-131




10-132



10-133




10-134




10-135


-continued




10-136




10-137




10-138




10-139




10-140




10-141




10-142




10-143




10-144




10-145



10-146




10-147
10-148
10-149
10-150
10-151
10-152
10-153
10-154
10-155
10-156




10-157
10-158
10-159
10-160
10-161
10-162
10-163
10-164
10-165
10-166


-continued




10-167




10-168




10-169




10-170




10-171



10-172




10-173




10-174


-continued




10-175




10-176




10-177




10-178




10-179




10-180



10-181




10-182




10-183


-continued




10-184




10-185




10-186




10-187




10-188



10-189




10-190




10-191


-continued




10-192




10-193




10-194




10-195




10-196




10-197



10-198




10-199




10-200


-continued




-continued




-continued




10-219




10-220




10-221




10-222




10-223



10-224




10-225




10-226


-continued




10-227




10-228




10-229




10-230




10-231



10-232




10-233




10-234

-continued



-continued



wherein Q_1 to Q_9 are each independently:

—CH₃, —CD₃, —CD₂H, —CDH₂, —CH₂CH₃,
 —CH₂CD₃, —CH₂CD₂H, —CH₂CDH₂, —CHDCD₃,
 —CHDCD₂H, —CHDCDH₂, —CHDCD₃, —CD₂CD₃,
 —CD₂CD₂H, and —CD₂CDH₂;

an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, a sec-pentyl group, a tert-pentyl group, a phenyl group, and a naphthyl group; and

[0084] an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, a sec-pentyl group, a tert-pentyl group, a phenyl group, and a naphthyl group, each substituted with at least one selected from deuterium, a C₁-C₁₀ alkyl group, and a phenyl group.

[0085] In Formulae 9-1 to 9-21 and 10-1 to 10-253:

[0086] * indicates a binding site to a neighboring atom,

[0087] i-Pr indicates an iso-propyl group, t-Bu indicates a tert-butyl group, and Ph indicates a phenyl group,

[0088] 1-Nph indicates a 1-naphthyl group and 2-Nph indicates a 2-naphthyl group,

[0089] 2-Pyr indicates a 2-pyridyl group, 3-Pyr indicates a 3-pyridyl group, and 4-Pyr indicates a 4-pyridyl group, and [0090] TMS indicates a trimethylsilyl group.

[0091] In one or more embodiments, in Formula 1, R_{11} to R_{13} may each independently be selected from hydrogen, deuterium, —F, a cyano group, a nitro group, —SF₅, —CH₃, —CF₃, groups represented by Formulae 9-1 to 9-13, and groups represented by Formulae 10-17 to 10-79, but embodiments of the present disclosure are not limited thereto.

[0092] In Formula 1, two, three, or four of a plurality of R_{11} to R_{13} that are adjacent to each other may be optionally linked to form a quadridentate, hexadentate, or octadentate ligand.

[0093] For example, in Formula 1, two groups R_{11} that are adjacent to each other may be optionally linked to form a quadridentate ligand, but embodiments of the present disclosure are not limited thereto.

[0094] In one or more embodiments, in Formula 1, two groups R_{12} that are adjacent to each other may be optionally linked to form a quadridentate ligand, but embodiments of the present disclosure are not limited thereto.

[0095] In one or more embodiments, in Formula 1, two groups R_{13} that are adjacent to each other may be optionally linked to form a quadridentate ligand, but embodiments of the present disclosure are not limited thereto.

[0096] For example, in Formula 1, three groups R_{11} that are adjacent to each other may be optionally linked to form a hexadentate ligand, but embodiments of the present disclosure are not limited thereto optionally.


[0097] In one or more embodiments, in Formula 1, three groups R_{12} that are adjacent to each other may be optionally linked to form a hexadentate ligand, but embodiments of the present disclosure are not limited thereto.

[0098] In one or more embodiments, in Formula 1, three groups R_{13} that are adjacent to each other may be optionally linked to form a hexadentate ligand, but embodiments of the present disclosure are not limited thereto.


[0099] In Formula 1, b_{12} indicates the number of R_{12} , and may be selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10. When b_{12} is two or more, a plurality of the R_{12} may be identical to or different from each other.

[0100] In Formula 1, b_{13} indicates the number of R_{13} , and may be selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10. When b_{13} is two or more, a plurality of the R_{13} may be identical to or different from each other.

[0101] In Formula 1, n_{11} may be a ligand represented by



(wherein * and *' each indicate a binding site to M_{11} in Formula 1), and may be selected from 1, 2, 3, and 4. When n_{11} is two or more, a ligand represented by



in Formula 1 may be identical to or different from each other.

[0102] For example, in Formula 1, n_{11} may be selected from 1, 2, and 3, but embodiments of the present disclosure are not limited thereto.

[0103] In Formula 1, n_{12} indicates the number of L_{12} , and may be selected from 0, 1, 2, and 3. When n_{12} is two or more, a plurality of the L_{12} in Formula 1 may be identical to or different from each other.


[0104] For example, in Formula 1, n_{12} may be selected from 0, 1, and 2, but embodiments of the present disclosure are not limited thereto.


[0105] In one or more embodiments, in Formula 1, M_{11} may be Ir, n_{11} may be selected from 1, 2, and 3, and n_{12} may be selected from 0, 1, and 2, but embodiments of the present disclosure are not limited thereto.

[0106] In Formula 1, L_{12} may be selected from a bidentate ligand.


[0107] For example, in Formula 1, L_{12} may be a bidentate ligand, and may be selected from oxalate, acetylacetonate, picolinic acid, 1,2-bis(diphenylphosphino)ethane, 1,1-bis(diphenylphosphino)methane, glycinate, and ethylenediamine, but embodiments of the present disclosure are not limited thereto.

[0108] In one or more embodiments, in Formula 1, L_{12} may be a ligand represented by one of Formulae 7-1 to 7-7, but embodiments of the present disclosure are not limited thereto:







7-4



7-5



7-6



7-7

[0109] wherein in Formulae 7-1 to 7-7,

[0110] A_{71} and A_{72} may each independently be selected from a C_5 - C_{20} carbocyclic group and a C_1 - C_{20} heterocyclic group,

[0111] X_{71} and X_{72} may each independently be selected from C and N,

[0112] X_{78} may be O, S, or $N(Q_{78})$,

[0113] X_{79} may be O, S, or $N(Q_{79})$,

[0114] Y_{71} and Y_{72} may each independently be selected from a single bond, a double bond, a substituted or unsubstituted C_1 - C_5 alkylene group, a substituted or unsubstituted C_2 - C_5 alkenylene group, and a substituted or unsubstituted C_6 - C_{10} arylene group,

[0115] Z_{71} and Z_{72} may each independently be selected from N, O, $N(R_{75})$, $P(R_{75})(R_{76})$, and $As(R_{75})(R_{76})$,

[0116] Z_{74} may be selected from CO and CH_2 ,

[0117] R_{71} , R_{72} , R_{75} to R_{80} , and Q_{73} to Q_{79} may each independently be selected from hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a substituted or unsubstituted C_1 - C_{60} alkyl group, a substituted or unsubstituted C_2 - C_{60} alkenyl group, a substituted or unsubstituted C_3 - C_{60} alkynyl group, a substituted or unsubstituted C_1 - C_{60} alkoxy group, a substituted or unsubstituted C_3 - C_{10} cycloalkyl group, a substituted or unsubstituted C_1 - C_{10} heterocycloalkyl group, a substituted or unsubstituted C_3 - C_{10} cycloalkenyl group, a substituted or unsubstituted C_1 - C_{10} heterocycloalkenyl group, a substituted or unsubstituted C_6 - C_{60} aryl group, a substituted or unsubstituted C_6 - C_{60} aryloxy group, a substituted or unsubstituted C_6 - C_{60} arylthio group, a substituted or unsubstituted C_1 - C_{60} heteroaryl group, a substituted or

unsubstituted monovalent non-aromatic condensed polycyclic group, and a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group,

[0118] R_{71} and R_{72} may optionally be linked to form a ring,

[0119] R_{77} and R_{78} may optionally be linked to form a ring,

[0120] R_{78} and R_{79} may optionally be linked to form a ring,

[0121] R_{79} and R_{80} may optionally be linked to form a ring,

[0122] b_{71} and b_{72} may each independently be selected from 1, 2, 3, 4, 5, and 6, and

[0123] * and *' each independently a binding site to a neighboring atom.

[0124] For example, in Formula 7-1, A_{71} and A_{72} may each independently be selected from a benzene group, a naphthalene group, an imidazole group, a benzimidazole group, a pyridine group, a pyrimidine group, a triazine group, a quinoline group, and an isoquinoline group, but embodiments of the present disclosure are not limited thereto.

[0125] For example, in Formula 7-1, X_{72} and X_{79} may each independently be N, but embodiments of the present disclosure are not limited thereto.

[0126] For example, in Formula 7-4, X_{78} may be $N(Q_{78})$, and X_{79} may be $N(Q_{79})$, but embodiments of the present disclosure are not limited thereto.

[0127] For example, in Formulae 7-2 to 7-5, and 7-7, Y_{71} and Y_{72} may each independently be selected from a substituted or unsubstituted methylene group and a substituted or unsubstituted phenylene group, but embodiments of the present disclosure are not limited thereto.

[0128] For example, in Formulae 7-1 and 7-2, Z_{71} and Z_{72} may each independently be O, but embodiments of the present disclosure are not limited thereto.

[0129] For example, in Formulae 7-1 to 7-7, R_{71} , R_{72} , R_{75} to R_{80} , and Q_{73} to Q_{79} may each independently be selected from:

[0130] hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C_1 - C_{20} alkyl group, and a C_1 - C_{20} alkoxy group;


[0131] a C_1 - C_{20} alkyl group and a C_1 - C_{20} alkoxy group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazine group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a phenyl group, a naphthyl group, a pyridinyl group, and a pyrimidinyl group,

[0132] a phenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinno-

linyl group, a carbazolyl group, a phenanthrolinyl group, a benzimidazolyl group, a benzofuranyl group, a benzothio-phenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetra-azolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzo-carbazolyl group, a dibenzocarbazolyl group, and an imida-zopyridinyl group; and


[0133] a phenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinoliny group, an isoquinoliny group, a benzoquinoliny group, a quinoxaliny group, a quinazoliny group, a cinnoliny group, a carbazolyl group, a phenanthrolinyl group, a benzimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetra-azolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzo-carbazolyl group, a dibenzocarbazolyl group, and an imida-zopyridinyl group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₂₀ alkyl group, a C₁-C₂₀ alkoxy group, a phenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinoliny group, an isoquinoliny group, a benzoquinoliny group, a quinoxaliny group, a quinazoliny group, a cinnoliny group, a carbazolyl group, a phenanthrolinyl group, a benzimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetra-azolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzo-carbazolyl group, a dibenzocarbazolyl group, and an imida-zopyridinyl group, but embodiments of the present disclosure are not limited thereto.

[0134] In one or more embodiments, in Formula 1, L₁₂ may be a ligand represented by one of Formulae 5-1 to 5-116 and 8-1 to 8-32, but embodiments of the present disclosure are not limited thereto:




8-1


-continued




8-2




8-3




8-4




8-5



8-6




8-7




8-8


-continued




8-9




8-10




8-11



8-12




8-13




8-14


-continued




8-15




8-16




8-17



8-18




8-19




8-20

-continued


8-27




8-28




8-29





8-30




8-31



8-32




-continued




5-2


-continued




5-7




5-3




5-8




5-4




5-9




5-5



5-10




5-6




5-11

-continued




5-12


-continued




5-17




5-13




5-18




5-14




5-19




5-15



5-20




5-16




5-21

-continued




5-22


-continued




5-27




5-23




5-28




5-24




5-29




5-25



5-30




5-26




5-31

-continued




5-32


-continued




5-37




5-33




5-38




5-34




5-39




5-35



5-40




5-36




5-41

-continued




5-42


-continued




5-47




5-43




5-48




5-44




5-49




5-45



5-50




5-46




5-51


-continued




5-52




5-53




5-54



5-55




5-56




5-57


-continued




5-58




5-59




5-60



5-61




5-62




5-63


-continued




5-64




5-65



5-66




5-67




5-68


-continued




5-69




5-70



5-71



5-72




5-73


-continued




-continued




5-84




5-85



5-86




5-87




5-88


-continued




5-89




5-90



5-91




5-92




5-93

-continued




5-94


-continued




5-99




5-95




5-100




5-96




5-101




5-97



5-102




5-98




5-103


-continued




5-104




5-105



5-106




5-107




5-108


-continued




5-109




5-110



5-111




5-112




5-113


-continued



5-114



5-115



5-116

[0135] In Formulae 5-1 to 5-116 and 8-1 to 8-32,

[0136] R_{51} to R_{53} may each independently be selected from hydrogen, —F, a cyano group, a nitro group, a methyl group, an ethyl group, a propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, a sec-pentyl group, a tert-pentyl group, an n-hexyl group, an iso-hexyl group, a sec-hexyl group, a tert-hexyl group, an n-heptyl group, an iso-heptyl group, a sec-heptyl group, a tert-heptyl group, an n-octyl group, an iso-octyl group, a sec-octyl group, a tert-octyl group, an n-nonyl group, an iso-nonyl group, a sec-nonyl group, a tert-nonyl group, an n-decanyl group, an iso-decanyl group, a sec-decanyl group, a tert-decanyl group, a methoxy group, an ethoxy group, a propoxy group, a butoxy group, a pentoxy group, a phenyl group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, a triazinyl group, a dibenzofuranyl group, and a dibenzothiophenyl group; and

[0137] a methyl group, an ethyl group, a propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an iso-pentyl group, a sec-pentyl group, a tert-pentyl group, an n-hexyl group, an iso-hexyl group, a sec-hexyl group, a tert-hexyl group, an n-heptyl group, an iso-heptyl group, a sec-heptyl group, a tert-heptyl group, an n-octyl group, an iso-octyl group, a sec-octyl group, a tert-octyl group, an n-nonyl group, an iso-nonyl group, a sec-nonyl group, a tert-nonyl group, an n-decanyl group, an iso-decanyl group, a sec-decanyl group, a tert-decanyl group, a methoxy group, an ethoxy group, a propoxy group, a butoxy group, a pentoxy group, a phenyl

group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, a triazinyl group, a dibenzofuranyl group, and a dibenzothiophenyl group, each substituted with at least one selected from —F, a cyano group, and a nitro group,

[0138] b_{51} and b_{54} may each independently be selected from 1 and 2,

[0139] b_{53} and b_{55} may each independently be selected from 1, 2, and 3,

[0140] b_{52} may be selected from 1, 2, 3, and 4,


[0141] Ph indicates a phenyl group,

[0142] Ph-d5 indicates a phenyl group of which all hydrogen atoms are substituted with deuterium, and


[0143] * and *' each indicate a binding site to a neighboring atom.

[0144] In one or more embodiments, the organometallic compound of Formula 1 may be represented by one of Formulae 1-1 to 1-4, but embodiments of the present disclosure are not limited thereto:


1-1



1-2




1-3



-continued

1-4



wherein, in Formulae 1-1 to 1-4,

[0145] M_{11} , R_{11} , n_{11} , n_{12} , and L_{12} are each independently the same as described in Formula 1,

[0146] R_{21} to R_{24} are each independently the same as described in connection with R_{12} in Formula 1, and

[0147] R_{31} to R_{34} are each independently the same as described in connection with R_{13} in Formula 1.

[0148] For example, in Formulae 1-1 to 1-4, R_{11} , R_{21} to R_{24} , and R_{31} to R_{34} may each independently be selected from:

[0149] hydrogen, deuterium, $-F$, $-Cl$, $-Br$, $-I$, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, $-SF_5$, C_1 - C_{20} alkyl group, and a C_1 - C_{20} alkoxy group;

[0150] a C_1 - C_{20} alkyl group and a C_1 - C_{20} alkoxy group, each substituted with at least one selected from deuterium, $-F$, $-Cl$, $-Br$, $-I$, $-CD_3$, $-CD_2H$, $-CDH_2$, $-CF_3$, $-CF_2H$, $-CFH_2$, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C_1 - C_{10} alkyl group, a cyclopentyl group, a cyclohexyl group, a cyclohexyl group substituted with deuterium, a cycloheptyl group, a cycloheptyl group substituted with deuterium, a cyclooctyl group, a cyclooctyl group substituted with deuterium, a bicyclo[2.2.1]heptanyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a pyridinyl group, and a pyrimidinyl group;

[0151] a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, a bicyclo[2.2.1]heptanyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthrenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolyl group, an isoquinolyl group, a

benzoquinolyl group, a quinoxalyl group, a quinazolyl group, a cinnolyl group, a carbazolyl group, a phenanthrolinyl group, a benzimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a dibenzosilolyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, and an imidazopyrimidinyl group;

[0152] a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, a bicyclo[2.2.1]heptanyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthrenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolyl group, an isoquinolyl group, a benzoquinolyl group, a quinoxalyl group, a quinazolyl group, a cinnolyl group, a carbazolyl group, a phenanthrolinyl group, a benzimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a dibenzosilolyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, and an imidazopyrimidinyl group, each substituted with at least one selected from deuterium, $-F$, $-Cl$, $-Br$, $-I$, $-CD_3$, $-CD_2H$, $-CDH_2$, $-CF_3$, $-CF_2H$, $-CFH_2$, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C_1 - C_{20} alkyl group, a C_1 - C_{20} alkoxy group, a cyclopentyl group, a cyclohexyl group, a cyclohexyl group substituted with deuterium, a cycloheptyl group, a cycloheptyl group substituted with deuterium, a cyclooctyl group, a cyclooctyl group substituted with deuterium, a bicyclo[2.2.1]heptanyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthrenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolyl group, an isoquinolyl group, a benzoquinolyl group, a quinoxalyl group, a quinazolyl group, a cinnolyl group, a carbazolyl group, a phenanthrolinyl group, a benzimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a

triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a dibenzosilolyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, and $-\text{Si}(\text{Q}_{33})(\text{Q}_{34})(\text{Q}_{35})$; and

[0153] $-\text{N}(\text{Q}_1)(\text{Q}_2)$, $-\text{Si}(\text{Q}_3)(\text{Q}_4)(\text{Q}_5)$, $-\text{B}(\text{Q}_6)(\text{Q}_7)$, and $-\text{P}(=\text{O})(\text{Q}_8)(\text{Q}_9)$, and

[0154] Q_1 to Q_9 and Q_{33} to Q_{35} may each independently be selected from:

[0155] $-\text{CH}_3$, $-\text{CD}_3$, $-\text{CD}_2\text{H}$, $-\text{CDH}_2$, $-\text{CH}_2\text{CH}_3$, $-\text{CH}_2\text{CD}_3$, $-\text{CH}_2\text{CD}_2\text{H}$, $-\text{CH}_2\text{CDH}_2$, $-\text{CHDC}_3$, $-\text{CHDCD}_2\text{H}$, $-\text{CHDCDH}_2$, $-\text{CHDCD}_3$, $-\text{CD}_2\text{CD}_3$, $-\text{CD}_2\text{CD}_2\text{H}$, and $-\text{CD}_2\text{CDH}_2$;

[0156] an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, a sec-pentyl group, a tert-pentyl group, a phenyl group, and a naphthyl group; and

[0157] an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, a sec-pentyl group, a tert-pentyl group, a phenyl group, and a naphthyl group, each substituted with at least one selected from deuterium, a C_1 - C_{10} alkyl group, and a phenyl group, but embodiments of the present disclosure are not limited thereto.

[0158] In one or more embodiments, in Formulae 1-1 to 1-4, R_{11} , R_{21} to R_{24} , and R_{31} to R_{34} may each independently be selected from:

[0159] hydrogen, deuterium, $-\text{F}$, a cyano group, a nitro group, $-\text{SF}_5$, a methyl group, an ethyl group, an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, a sec-pentyl group, a tert-pentyl group, an n-hexyl group, an iso-hexyl group, a sec-hexyl group, a tert-hexyl group, an n-heptyl group, an iso-heptyl group, a sec-heptyl group, a tert-heptyl group, an n-octyl group, an iso-octyl group, a sec-octyl group, a tert-octyl group, an n-nonyl group, an iso-nonyl group, a sec-nonyl group, a tert-nonyl group, an n-decyl group, an iso-decyl group, a sec-decyl group, a tert-decyl group, a methoxy group, an ethoxy group, a propoxy group, a butoxy group, a pentoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, a bicyclo[2.2.1]heptanyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, a fluorenyl group, a carbazolyl group, a dibenzofuranyl group, a dibenzothiophenyl group, and a dibenzosilolyl group;

[0160] a methyl group, an ethyl group, an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, a sec-pentyl group, a tert-pentyl group, an n-hexyl group, an iso-hexyl group, a sec-hexyl group, a tert-hexyl group, an n-heptyl group, an iso-heptyl group, a sec-heptyl group, a tert-heptyl group, an n-octyl group, an iso-octyl group, a sec-octyl group, a tert-octyl group, an n-nonyl group, an iso-nonyl group, a sec-nonyl group, a tert-nonyl group, an n-decyl group, an iso-decyl group, a sec-decyl group, a tert-decyl group, a methoxy group, an ethoxy group, a propoxy group, a butoxy group, a pentoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, a bicyclo[2.2.1]heptanyl group, an adamantanyl group, a norbornanyl group, a nor-

bornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, a fluorenyl group, a carbazolyl group, a dibenzofuranyl group, a dibenzothiophenyl group, and a dibenzosilolyl group, each substituted with at least one selected from deuterium, $-\text{F}$, $-\text{CD}_3$, $-\text{CD}_2\text{H}$, $-\text{CDH}_2$, $-\text{CF}_3$, $-\text{CF}_2\text{H}$, $-\text{CFH}_2$, a cyano group, a nitro group, a C_1 - C_{10} alkyl group, a C_1 - C_{10} alkoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, a bicyclo[2.2.1]heptanyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, a fluorenyl group, a carbazolyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a dibenzosilolyl group, and $-\text{Si}(\text{Q}_{33})(\text{Q}_{34})(\text{Q}_{35})$; and

[0161] $-\text{N}(\text{Q}_1)(\text{Q}_2)$, $-\text{Si}(\text{Q}_3)(\text{Q}_4)(\text{Q}_5)$, $-\text{B}(\text{Q}_6)(\text{Q}_7)$, and $-\text{P}(=\text{O})(\text{Q}_8)(\text{Q}_9)$, and


[0162] Q_1 to Q_9 and Q_{33} to Q_{35} may each independently be selected from:

[0163] $-\text{CH}_3$, $-\text{CD}_3$, $-\text{CD}_2\text{H}$, $-\text{CDH}_2$, $-\text{CH}_2\text{CH}_3$, $-\text{CH}_2\text{CD}_3$, $-\text{CH}_2\text{CD}_2\text{H}$, $-\text{CH}_2\text{CDH}_2$, $-\text{CHDC}_3$, $-\text{CHDCD}_2\text{H}$, $-\text{CHDCDH}_2$, $-\text{CHDCD}_3$, $-\text{CD}_2\text{CD}_3$, $-\text{CD}_2\text{CD}_2\text{H}$, and $-\text{CD}_2\text{CDH}_2$;






[0164] an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, a sec-pentyl group, a tert-pentyl group, a phenyl group, and a naphthyl group; and

[0165] an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, a sec-pentyl group, a tert-pentyl group, a phenyl group, and a naphthyl group, each substituted with at least one selected from deuterium, a C_1 - C_{10} alkyl group, and a phenyl group, but embodiments of the present disclosure are not limited thereto.

[0166] In one or more embodiments, the organometallic compound of Formula 1 may be selected from Compounds 1 to 8, but embodiments of the present disclosure are not limited thereto:




-continued



-continued


2



7

8

3



4

[0167] The organometallic compound of Formula 1 may have a maximum emission wavelength (measured value) in a range of about 440 nanometers (nm) or more to about less than 500 nm, for example, in a range of about 440 nm to about 495 nm. While not wishing to be bound by theory, it is understood that when the maximum emission wavelength of the organometallic compound of Formula 1 is within a range of about 440 nm to about 495 nm, dark blue light may be emitted from an organic light-emitting device including the organometallic compound of Formula 1.

5

[0168] The organometallic compound of Formula 1 always includes a nitrogen atom-containing C_1 - C_{30} heterocyclic group represented by A_{11} , and accordingly, may have a shallow lowest unoccupied molecular orbital (LUMO) energy level. In this regard, the organometallic compound of Formula 1 may have the broader band gap resulting in the higher triplet energy level. Thus, dark blue emission light may be emitted from an organic light-emitting device including the organometallic compound of Formula 1.

6

[0169] The organometallic compound of Formula 1 may have a triplet energy level suitable for blue light and relatively short fluorescence lifetime. Therefore, the organometallic compound of Formula 1 may serve as a blue dopant with a high absolute quantum yield.

[0170] Synthesis methods of the organometallic compound of Formula 1 may be recognizable by one of ordinary skill in the art by referring to Synthesis Examples provided below.

[0171] The organometallic compound of Formula 1 may be suitable for use in an organic layer of an organic light-emitting device, for example, for use as a dopant in an emission layer of the organic layer. Thus, another aspect of the present description provides an organic light-emitting device that includes: a first electrode; a second electrode; and an organic layer that is disposed between the first electrode and the second electrode, wherein the organic

layer includes an emission layer, and wherein the organic layer further includes at least one organometallic compound represented by Formula 1.

[0172] The organic light-emitting device may have, due to the inclusion of an organic layer including the organometallic compound represented by Formula 1, a low driving voltage, high efficiency, high power, high quantum efficiency, a long lifespan, a low roll-off ratio, and excellent color purity.

[0173] The organometallic compound of Formula 1 may be used between a pair of electrodes of an organic light-emitting device. For example, the organometallic compound represented by Formula 1 may be included in the emission layer. In this regard, the organometallic compound may act as a dopant, and the emission layer may further include a host (that is, an amount of the organometallic compound represented by Formula 1 is smaller than an amount of the host). In this regard, the dopant may emit blue light.

[0174] The expression “(an organic layer) includes at least one organometallic compound” as used herein may include an embodiment in which “(an organic layer) includes identical compounds represented by Formula 1” and an embodiment in which “(an organic layer) includes two or more different organometallic compounds represented by Formula 1.”

[0175] For example, the organic layer may include, as the organometallic compound, only Compound 1. In this regard, Compound 1 may be included in an emission layer of the organic light-emitting device. In one or more embodiments, the organic layer may include, as the organometallic compound, Compound 1 and Compound 2. In this regard, Compound 1 and Compound 2 may be included in an identical layer (for example, Compound 1 and Compound 2 may be included in an emission layer).

[0176] The first electrode may be an anode, which is a hole injection electrode, and the second electrode may be a cathode, which is an electron injection electrode; or the first electrode may be a cathode, which is an electron injection electrode, and the second electrode may be an anode, which is a hole injection electrode.

[0177] In one or more embodiments, in the organic light-emitting device, the first electrode is an anode, and the second electrode is a cathode, and the organic layer further includes a hole transport region disposed between the first electrode and the emission layer and an electron transport region disposed between the emission layer and the second electrode, wherein the hole transport region includes at least one selected from a hole injection layer, a hole transport layer, and an electron blocking layer, and wherein the electron transport region includes at least one selected from a hole blocking layer, an electron transport layer, and an electron injection layer.

[0178] The term “organic layer” as used herein refers to a single layer and/or a plurality of layers disposed between the first electrode and the second electrode of the organic light-emitting device. The “organic layer” may include, in addition to an organic compound, an organometallic compound including metal.

[0179] FIG. 1 is a schematic view of an organic light-emitting device 10 according to an embodiment. Hereinafter, the structure of an organic light-emitting device according to an embodiment and a method of manufacturing an organic light-emitting device according to an embodiment will be described in connection with FIG. 1. The organic

light-emitting device 10 includes a first electrode 11, an organic layer 15, and a second electrode 19, which are sequentially stacked.

[0180] A substrate may be additionally disposed under the first electrode 11 or above the second electrode 19. For use as the substrate, any substrate that is used in general organic light-emitting devices may be used, and the substrate may be a glass substrate or a transparent plastic substrate, each having excellent mechanical strength, thermal stability, transparency, surface smoothness, ease of handling, and water resistance.

[0181] In one or more embodiments, the first electrode 11 may be formed by depositing or sputtering a material for forming the first electrode 11 on the substrate. The first electrode 11 may be an anode. The material for forming the first electrode 11 may be selected from materials with a high work function to facilitate hole injection. The first electrode 11 may be a reflective electrode, a semi-transmissive electrode, or a transmissive electrode. The material for forming the first electrode 11 may be indium tin oxide (ITO), indium zinc oxide (IZO), tin oxide (SnO₂), or zinc oxide (ZnO). In one or more embodiments, the material for forming the first electrode 11 may be metal, such as magnesium (Mg), aluminum (Al), aluminum-lithium (Al—Li), calcium (Ca), magnesium-indium (Mg—In), or magnesium-silver (Mg—Ag).

[0182] The first electrode 11 may have a single-layered structure or a multi-layered structure including two or more layers. For example, the first electrode 11 may have a three-layered structure of ITO/Ag/ITO, but the structure of the first electrode 11 is not limited thereto.

[0183] The organic layer 15 is disposed on the first electrode 11.

[0184] The organic layer 15 may include a hole transport region, an emission layer, and an electron transport region.

[0185] The hole transport region may be disposed between the first electrode 11 and the emission layer.

[0186] The hole transport region may include at least one selected from a hole injection layer, a hole transport layer, an electron blocking layer, and a buffer layer.

[0187] The hole transport region may include only either a hole injection layer or a hole transport layer. In one or more embodiments, the hole transport region may have a hole injection layer/hole transport layer structure or a hole injection layer/hole transport layer/electron blocking layer structure, which are sequentially stacked in this stated order from the first electrode 11.

[0188] When the hole transport region includes a hole injection layer, the hole injection layer may be formed on the first electrode 11 by using one or more suitable methods, for example, vacuum deposition, spin coating, casting, and/or Langmuir-Blodgett (LB) deposition.


[0189] When a hole injection layer is formed by vacuum deposition, the deposition conditions may vary according to a material that is used to form the hole injection layer, and the structure and thermal characteristics of the hole injection

layer. For example, the deposition conditions may include a deposition temperature in a range of about 100° C. to about 500° C., a vacuum pressure in a range of about 10^{-8} torr to about 10^{-3} torr, and a deposition rate in a range of about 0 Angstroms per second (Å/sec) to about 100 Å/sec. However, the deposition conditions are not limited thereto.




[0190] When the hole injection layer is formed using spin coating, coating conditions may vary according to the material used to form the hole injection layer, and the structure and thermal properties of the hole injection layer. For example, a coating speed may be in a range of about 2,000 revolutions per minute (rpm) to about 5,000 rpm, and a temperature at which a heat treatment is performed to remove a solvent after coating may be in a range of about 80° C. to about 200° C. However, the coating conditions are not limited thereto.

[0191] Conditions for forming a hole transport layer and an electron blocking layer may be understood by referring to conditions for forming the hole injection layer.


[0192] The hole transport region may include at least one selected from, for example, m-MTDATA, TDATA, 2-TNATA, NPB, R-NPB, TPD, spiro-TPD, spiro-NPB, methylated-NPB, TAPC, HMTPD, 4,4',4"-tris(N-carbazolyl)triphenylamine (TCTA), polyaniline/dodecylbenzene sulfonic acid (PANI/DBSA), poly(3,4-ethylenedioxythiophene)/poly(4-styrene sulfonate) (PEDOT/PSS), polyaniline/camphor sulfonic acid (PANI/CSA), polyaniline/poly(4-styrene sulfonate) (PANI/PSS), a compound represented by Formula 201, and a compound represented by Formula 202:




-continued




-continued

 β -NPB


-continued



TAPC




TPD




HMTPD


Formula 201




Spiro-TPD




Formula 202



Spiro-NPD



methylated NPB



[0193] In Formula 201, Ar_{101} and Ar_{102} may each independently be selected from:

[0194] a phenylene group, a pentalenylene group, an indenylene group, a naphthylene group, an azulenylene group, a heptalenylene group, an acenaphthylene group, a fluore-

nylene group, a phenalenylene group, a phenanthrenylene group, an anthracenylene group, a fluoranthenylene group, a triphenylenylene group, a pyrenylene group, a chrysene-nylene group, a naphthacenylene group, a picenylene group, a perylenylene group, and a pentacenylene group; and

[0195] a phenylene group, a pentalenylene group, an indenylene group, a naphthylene group, an azulenylene group, a heptalenylene group, an acenaphthylene group, a fluorenylene group, a phenalenylene group, a phenanthrenylene group, an anthracenylene group, a fluoranthenylene group, a triphenylenylene group, a pyrenylene group, a chrysene-nylene group, a naphthacenylene group, a picenylene group, a perylenylene group, and a pentacenylene group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C_1 - C_{60} alkyl group, a C_2 - C_{60} alkenyl group, a C_2 - C_{60} alkynyl group, a C_1 - C_{60} alkoxy group, a C_3 - C_{10} cycloalkyl group, a C_3 - C_{10} cycloalkenyl group, a C_1 - C_{10} heterocycloalkyl group, a C_1 - C_{10} heterocycloalkenyl group, a C_6 - C_{60} aryl group, a C_6 - C_{60} aryloxy group, a C_6 - C_{60} arylthio group, a C_1 - C_{60} heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group.

[0196] In Formula 201, xa and xb may each independently be an integer from 0 to 5, or may be 0, 1, or 2. For example, xa may be 1 and xb may be 0, but xa and xb are not limited thereto.

[0197] In Formulae 201 and 202, R_{101} to R_{108} , R_{111} to R_{119} , and R_{121} to R_{124} may each independently be selected from:

[0198] hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C_1 - C_{10} alkyl group (for example, a methyl group, an ethyl group, a propyl group, a butyl group, pentyl group, or a hexyl group), and C_1 - C_{10} alkoxy group (for example, a methoxy group, an ethoxy group, a propoxy group, a butoxy group, or a pentoxy group);

[0199] a C_1 - C_{10} alkyl group and a C_1 - C_{10} alkoxy group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, and a phosphoric acid group or a salt thereof;

[0200] a phenyl group, a naphthyl group, an anthracenyl group, a fluorenyl group, and a pyrenyl group; and

[0201] a phenyl group, a naphthyl group, an anthracenyl group, a fluorenyl group, and a pyrenyl group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C_1 - C_{10} alkyl group, and a C_1 - C_{10} alkoxy group, but embodiments of the present disclosure are not limited thereto.


[0202] In Formula 201, R_{109} may be selected from:

[0203] a phenyl group, a naphthyl group, an anthracenyl group, and a pyridinyl group; and

[0204] a phenyl group, a naphthyl group, an anthracenyl group, and a pyridinyl group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C_1 - C_{20} alkyl group, a C_1 - C_{20} alkoxy group, a phenyl group, a naphthyl group, an anthracenyl group, and a pyridinyl group.

[0205] In one or more embodiments, the compound of Formula 201 may be represented by Formula 201A below, but embodiments of the present disclosure are not limited thereto:


Formula 201A



[0206] In Formula 201A, R_{101} , R_{111} , R_{112} , and R_{109} are the same as described above.

[0207] For example, the compound of Formula 201 and the compound of Formula 202 may include Compounds HT1 to HT20, but are not limited thereto:

HT1





-continued

-continued



HT2

HT4



HT3

HT5





-continued

-continued



HT8

HT6




HT9


HT7




HT10




-continued



HT12




HT13




-continued


HT14




HT15



HT16




HT17




-continued


HT18



HT19



HT20




[0208] A thickness of the hole transport region may be in a range of about 100 Angstroms (Å) to about 10,000 Å, for example, about 100 Å to about 1,000 Å. When the hole transport region includes both a hole injection layer and a hole transport layer, a thickness of the hole injection layer may be in a range of about 100 Å to about 10,000 Å, for example, about 100 Å to about 1,000 Å, and a thickness of the hole transport layer may be in a range of about 50 Å to about 2,000 Å, for example about 100 Å to about 1,500 Å. While not wishing to be bound by theory, it is understood that when the thicknesses of the hole transport region, the hole injection layer, and the hole transport layer are within these ranges, satisfactory hole transporting characteristics may be obtained without a substantial increase in driving voltage.

[0209] The hole transport region may further include, in addition to these materials, a charge-generation material for the improvement of conductive properties. The charge-


generation material may be homogeneously or non-homogeneously dispersed in the hole transport region.

[0210] The charge-generation material may be, for example, a p-dopant. The p-dopant may be one selected from a quinone derivative, a metal oxide, and a cyano group-containing compound, but embodiments of the present disclosure are not limited thereto. Non-limiting examples of the p-dopant are a quinone derivative, such as tetracyanoquinonedimethane (TCNQ) or 2,3,5,6-tetrafluoro-tetracyano-1,4-benzoquinonedimethane (F4-TCNQ); a metal oxide, such as a tungsten oxide or a molybdenum oxide; and a cyano group-containing compound, such as Compound HT-D1 or Compound HT-D2, but are not limited thereto:


HT-D1



F4-TCNQ



HT-D2



[0211] The hole transport region may include a buffer layer.

[0212] Also, the buffer layer may compensate for an optical resonance distance according to a wavelength of light emitted from the emission layer, and thus, efficiency of a formed organic light-emitting device may be improved.


[0213] Then, an emission layer may be formed on the hole transport region by vacuum deposition, spin coating, casting, LB deposition, or the like. When the emission layer is formed by vacuum deposition or spin coating, the deposition or coating conditions may be similar to those applied in forming the hole injection layer although the deposition or

coating conditions may vary according to a compound that is used to form the emission layer.


[0214] Meanwhile, when the hole transport region includes an electron blocking layer, a material for the electron blocking layer may be selected from materials for the hole transport region described above and materials for a host to be explained later. However, the material for the electron blocking layer is not limited thereto. For example, when the hole transport region includes an electron blocking layer, a material for the electron blocking layer may be mCP, which will be explained later.

[0215] The emission layer may include a host and a dopant, and the dopant may include the organometallic compound represented by Formula 1.


[0216] The host may include at least one selected from TPBi, TBADN, ADN (also referred to as "DNA"), CBP, CDBP, TCP, mCP, Compound H50, and Compound H51:



TPBi




TBADN




ADN


-continued




CBP



CDBP




TCP




mCP

Compound H50




-continued

Compound H51




H52



[0217] In one or more embodiments, the host may further include a compound represented by Formula 301:

Formula 301



[0218] In Formula 301, Ar₁₁₁ and Ar₁₁₂ may each independently be selected from:

[0219] a phenylene group, a naphthylene group, a phenanthrenylene group, and a pyrenylene group; and

[0220] a phenylene group, a naphthylene group, a phenanthrenylene group, and a pyrenylene group, each substituted with at least one selected from a phenyl group, a naphthyl group, and an anthracenyl group.

[0221] In Formula 301, Ar₁₁₃ to Ar₁₁₆ may each independently be selected from:

[0222] a C₁-C₁₀ alkyl group, a phenyl group, a naphthyl group, a phenanthrenyl group, and a pyrenyl group; and

[0223] a phenyl group, a naphthyl group, a phenanthrenyl group, and a pyrenyl group, each substituted with at least one selected from a phenyl group, a naphthyl group, and an anthracenyl group.


[0224] In Formula 301, g, h, i, and j may each independently be an integer from 0 to 4, and may be, for example, 0, 1, or 2.

[0225] In Formula 301, Ar₁₁₃ to Ar₁₁₆ may each independently be selected from:

[0226] a C₁-C₁₀ alkyl group substituted with at least one selected from a phenyl group, a naphthyl group, and an anthracenyl group;

[0227] a phenyl group, a naphthyl group, an anthracenyl group, a pyrenyl group, a phenanthrenyl group, and a fluorenyl group;


[0228] a phenyl group, a naphthyl group, an anthracenyl group, a pyrenyl group, a phenanthrenyl group, and a fluorenyl group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a C₁-C₆₀ alkyl group, a C₂-C₆₀ alkenyl group, a C₂-C₆₀ alkynyl group, a C₁-C₆₀ alkoxy group, a phenyl group, a naphthyl group, an anthracenyl group, a pyrenyl group, a phenanthrenyl group, and a fluorenyl group; and



but embodiments of the present disclosure are not limited thereto.

[0229] In one or more embodiments, the host may include a compound represented by Formula 302 below:

[0230] Formula 302




[0231] In Formula 302, Ar₁₂₂ to Ar₁₂₅ are the same as described in connection with Ar₁₁₃ in Formula 301.

[0232] In Formula 302, Ar₁₂₆ and Ar₁₂₇ may each independently be a C₁-C₁₀ alkyl group (for example, a methyl group, an ethyl group, or a propyl group).


[0233] In Formula 302, k and l may each independently be an integer from 0 to 4. For example, k and l may be 0, 1, or 2.

[0234] The compound of Formula 301 and the compound of Formula 302 may include Compounds H1 to H42, but are not limited thereto.


H1




-continued




H2




H3




H4



H5




H6




H7


-continued




H8




H9



H10




H11




H12

-continued


H13




H14




H15



H16




H17




-continued


H18




H19




H20



H21




H22




-continued

H23




-continued


H28




H24




H29




H25




H30




H26




H31




H27



H32




-continued




H33


-continued




H36




H34



H37




H35



H38


-continued

H39




-continued


H42



H40



H41



[0235] When the organic light-emitting device is a full-color organic light-emitting device, the emission layer may be patterned into a red emission layer, a green emission layer, and a blue emission layer. In one or more embodiments, due to a stacked structure including a red emission layer, a green emission layer, and/or a blue emission layer, the emission layer may emit white light.

[0236] When the emission layer includes a host and a dopant, an amount of the dopant may be in a range of about 0.01 part to about 15 parts by weight based on 100 parts by weight of the host, but embodiments of the present disclosure are not limited thereto.

[0237] The dopant may include at least one organometallic compound of Formula 1.

[0238] A thickness of the emission layer may be in a range of about 100 Å to about 1,000 Å, for example, about 200 Å to about 600 Å. When the thickness of the emission layer is within this range, excellent light-emission characteristics may be obtained without a substantial increase in driving voltage.


[0239] Then, an electron transport region may be disposed on the emission layer.

[0240] The electron transport region may include at least one selected from a hole blocking layer, an electron transport layer, and an electron injection layer.


[0241] For example, the electron transport region may have a hole blocking layer/electron transport layer/electron injection layer structure or an electron transport layer/electron injection layer structure, but the structure of the electron transport region is not limited thereto. The electron transport layer may have a single-layered structure or a multi-layered structure including two or more different materials.

[0242] Conditions for forming the hole blocking layer, the electron transport layer, and the electron injection layer which constitute the electron transport region may be understood by referring to the conditions for forming the hole injection layer.

[0243] When the electron transport region includes a hole blocking layer, the hole blocking layer may include, for example, at least one of BCP, Bphen, and BA1q but embodiments of the present disclosure are not limited thereto:




BCP




Bphen

[0244] A thickness of the hole blocking layer may be in a range of about 20 Å to about 1,000 Å, for example, about 30 Å to about 300 Å. While not wishing to be bound by theory, it is understood that when the thickness of the hole blocking layer is within these ranges, the hole blocking layer may have excellent hole blocking characteristics without a substantial increase in driving voltage.


[0245] The electron transport layer may further include at least one selected from BCP, Bphen, Alq₃, BA1q, TAZ, and NTAZ:

Alq₃


-continued



BA1q




TAZ



NTAZ


[0246] In one or more embodiments, the electron transport layer may include at least one of ET1 and ET25, but are not limited thereto:

ET1




-continued

ET2




-continued


ET5




ET3




ET6



ET4




ET7




-continued

ET8




-continued

ET11




ET12




ET13


ET9




ET10



ET14




-continued




ET15


ET16




ET17



ET18




-continued




ET19


ET20



ET21




-continued



ET22

-continued

ET25




ET23


[0247] A thickness of the electron transport layer may be in a range of about 100 Å to about 1,000 Å, for example, about 150 Å to about 500 Å. While not wishing to be bound by theory, it is understood that when the thickness of the electron transport layer is within the range described above, the electron transport layer may have satisfactory electron transport characteristics without a substantial increase in driving voltage.

[0248] Also, the electron transport layer may further include, in addition to the materials described above, a metal-containing material.

[0249] The metal-containing material may include a Li complex. The Li complex may include, for example, Compound ET-D1 (lithium 8-hydroxyquinolate, LiQ) or ET-D2:




ET-D1



ET24

ET-D2



[0250] The electron transport region may include an electron injection layer that promotes flow of electrons from the second electrode **19** thereinto.

[0251] The electron injection layer may include at least one selected from LiF, NaCl, CsF, Li₂O, and BaO.

[0252] A thickness of the electron injection layer may be in a range of about 1 Å to about 100 Å, for example, about 3 Å to about 90 Å. While not wishing to be bound by theory, it is understood that when the thickness of the electron

injection layer is within the range described above, the electron injection layer may have satisfactory electron injection characteristics without a substantial increase in driving voltage.

[0253] The second electrode **19** is disposed on the organic layer **15**. The second electrode **19** may be a cathode. A material for forming the second electrode **19** may be metal, an alloy, an electrically conductive compound, or a combination thereof, which have a relatively low work function. For example, lithium (Li), magnesium (Mg), aluminum (Al), aluminum-lithium (Al—Li), calcium (Ca), magnesium-indium (Mg—In), or magnesium-silver (Mg—Ag) may be formed as the material for forming the second electrode **19**. To manufacture a top-emission type light-emitting device, a transmissive electrode formed using ITO or IZO may be used as the second electrode **19**.

[0254] Hereinbefore, the organic light-emitting device has been described with reference to FIG. **1**, but embodiments of the present disclosure are not limited thereto.

[0255] The term “first-row transition metals” as used herein refers to d-block elements from Period 4 of the Periodic Table of Elements, and examples thereof are scandium (Sc), titanium (Ti), vanadium (V), chromium (Cr), manganese (Mn), iron (Fe), cobalt (Co), nickel (Ni), copper (Cu), and zinc (Zn).

[0256] The term “second-row transition metals” as used herein refers to d-block elements from Period 5 of the Periodic Table of Elements, and examples thereof are yttrium (Y), zirconium (Zr), niobium (Nb), molybdenum (Mo), technetium (Tc), ruthenium (Ru), rhodium (Rh), palladium (Pd), silver (Ag), and cadmium (Cd).

[0257] The term “third-row transition metals” as used herein refers to d-block and f-block elements of Period 6 of the Periodic Table of Elements, and examples thereof are lanthanum (La), samarium (Sm), europium (Eu), terbium (Tb), thulium (Tm), ytterbium (Yb), lutetium (Lu), hafnium (Hf), tantalum (Ta), tungsten (W), rhenium (Re), osmium (Os), iridium (Ir), platinum (Pr), gold (Au), and mercury (Hg).

[0258] The term “first-row post-transition metals” as used herein refers to elements that belong to Period 4 of the Periodic Table of Elements but are not transition metals, typical elements, and metalloid elements, and an example thereof is gallium (Ga).

[0259] The term “second-row post-transition metals” as used herein refers to elements that belong to Period 5 of the Periodic Table of Elements but are not transition metals, typical elements, and metalloid elements, and examples thereof are indium (In) and tin (Sn).

[0260] The term “third-row post-transition metals” as used herein refers elements that belong to Period 6 of the Periodic Table of Elements but are not transition metals, typical elements, and metalloid elements, and examples thereof are thallium (Tl), lead (Pb), and bismuth (Bi).

[0261] The term “C₁-C₆₀ alkyl group” as used herein refers to a linear or branched aliphatic saturated hydrocarbon monovalent group having 1 to 60 carbon atoms, and examples thereof include a methyl group, an ethyl group, a propyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, a pentyl group, an iso-amyl group, and a hexyl group. The term “C₁-C₆₀ alkylene group” as used herein refers to a divalent group having the same structure as the C₁-C₆₀ alkyl group.

[0262] The term “C₁-C₆₀ alkoxy group” as used herein refers to a monovalent group represented by —OA₁₀₁ (wherein A₁₀₁ is the C₁-C₆₀ alkyl group), and examples thereof include a methoxy group, an ethoxy group, and an iso-propyloxy group.

[0263] The term “C₂-C₆₀ alkenyl group” as used herein refers to a hydrocarbon group formed by including at least one carbon-carbon double bond in the middle or at the terminus of the C₂-C₆₀ alkyl group, and examples thereof include an ethenyl group, a propenyl group, and a butenyl group. The term “C₂-C₆₀ alkenylene group” as used herein refers to a divalent group having the same structure as the C₂-C₆₀ alkenyl group.

[0264] The term “C₆₀-C₆₀ alkynyl group” as used herein refers to a hydrocarbon group formed by including at least one carbon-carbon triple bond in the middle or at the terminus of the C₂-C₆₀ alkyl group, and examples thereof include an ethynyl group, and a propynyl group. The term “C₂-C₆₀ alkynylene group” as used herein refers to a divalent group having the same structure as the C₂-C₆₀ alkynyl group.

[0265] The term “C₃-C₁₀ cycloalkyl group” as used herein refers to a monovalent saturated hydrocarbon monocyclic group having 3 to 10 carbon atoms, and non-limiting examples thereof include a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, and a cycloheptyl group. The term “C₃-C₁₀ cycloalkylene group” as used herein refers to a divalent group having the same structure as the C₃-C₁₀ cycloalkyl group.

[0266] The term “C₁-C₁₀ heterocycloalkyl group” as used herein refers to a monovalent saturated monocyclic group having at least one heteroatom selected from N, O, P, Si and S as a ring-forming atom and 1 to 10 carbon atoms, and non-limiting examples thereof include a tetrahydrofuranlyl group, and a tetrahydrothiophenyl group. The term “C₁-C₁₀ heterocycloalkylene group” as used herein refers to a divalent group having the same structure as the C₁-C₁₀ heterocycloalkyl group.

[0267] The term “C₃-C₁₀ cycloalkenyl group” as used herein refers to a monovalent monocyclic group that has 3 to 10 carbon atoms and at least one carbon-carbon double bond in the ring thereof and no aromaticity, and non-limiting examples thereof include a cyclopentenyl group, a cyclohexenyl group, and a cycloheptenyl group. The term “C₃-C₁₀ cycloalkenylene group” as used herein refers to a divalent group having the same structure as the C₃-C₁₀ cycloalkenyl group.

[0268] The term “C₁-C₁₀ heterocycloalkenyl group” as used herein refers to a monovalent monocyclic group that has at least one heteroatom selected from N, O, P, Si, and S as a ring-forming atom, 1 to 10 carbon atoms, and at least one carbon-carbon double bond in its ring. Examples of the C₁-C₁₀ heterocycloalkenyl group are a 2,3-dihydrofuranlyl group, and a 2,3-dihydrothiophenyl group. The term “C₁-C₁₀ heterocycloalkenylene group” as used herein refers to a divalent group having the same structure as the C₁-C₁₀ heterocycloalkenyl group.

[0269] The term “C₆-C₆₀ aryl group” as used herein refers to a monovalent group having a carbocyclic aromatic system having 6 to 60 carbon atoms, and the term “C₆-C₆₀ arylene group” as used herein refers to a divalent group having a carbocyclic aromatic system having 6 to 60 carbon atoms. Non-limiting examples of the C₆-C₆₀ aryl group include a phenyl group, a naphthyl group, an anthracenyl group, a

phenanthrenyl group, a pyrenyl group, and a chrysenyl group. When the C₆-C₆₀ aryl group and the C₆-C₆₀ arylene group each include two or more rings, the rings may be fused to each other.

[0270] The term “C₁-C₆₀ heteroaryl group” as used herein refers to a monovalent group having a heterocyclic aromatic system that has at least one heteroatom selected from N, O, P, Si, and S as a ring-forming atom, and 1 to 60 carbon atoms. The term “C₁-C₆₀ heteroarylene group” as used herein refers to a divalent group having a heterocyclic aromatic system that has at least one heteroatom selected from N, O, P, and S as a ring-forming atom, and 1 to 60 carbon atoms. Non-limiting examples of the C₁-C₆₀ heteroaryl group include a pyridinyl group, a pyrimidinyl group, a pyrazinyl group, a pyridazinyl group, a triazinyl group, a quinolinyl group, and an isoquinolinyl group. When the C₁-C₆₀ heteroaryl group and the C₁-C₆₀ heteroarylene group each include two or more rings, the rings may be fused to each other.

[0271] The term “C₆-C₆₀ aryloxy group” as used herein indicates —OA₁₀₂ (wherein A₁₀₂ is the C₆-C₆₀ aryl group), and a C₆-C₆₀ arylthio group used herein indicates —SA₁₀₃ (wherein A₁₀₃ is the C₆-C₆₀ aryl group).

[0272] The term “monovalent non-aromatic condensed polycyclic group” as used herein refers to a monovalent group (for example, having 8 to 60 carbon atoms) having two or more rings condensed to each other, only carbon atoms as ring-forming atoms, and no aromaticity in its entire molecular structure. Examples of the monovalent non-aromatic condensed polycyclic group include a fluorenyl group. The term “divalent non-aromatic condensed polycyclic group,” as used herein refers to a divalent group having the same structure as the monovalent non-aromatic condensed polycyclic group.

[0273] The term “monovalent non-aromatic condensed heteropolycyclic group” as used herein refers to a monovalent group (for example, having 2 to 60 carbon atoms) having two or more rings condensed to each other, a heteroatom selected from N, O, P, Si, and S, other than carbon atoms, as a ring-forming atom, and no aromaticity in its entire molecular structure. Non-limiting examples of the monovalent non-aromatic condensed heteropolycyclic group include a carbazolyl group. The term “divalent non-aromatic condensed heteropolycyclic group” as used herein refers to a divalent group having the same structure as the monovalent non-aromatic condensed heteropolycyclic group.

[0274] The term “C₅-C₃₀ carbocyclic group” as used herein refers to a saturated or unsaturated cyclic group having, as a ring-forming atom, 5 to 30 carbon atoms only. The term “C₅-C₃₀ carbocyclic group” as used herein refers to a monocyclic group or a polycyclic group, and, according to its chemical structure, a monovalent, divalent, trivalent, tetravalent, pentavalent, or hexavalent group.

[0275] The term “C₁-C₃₀ heterocyclic group” as used herein refers to a saturated or unsaturated cyclic group having, as a ring-forming atom, at least one heteroatom selected from N, O, Si, P, and S other than 1 to 30 carbon atoms. The term “C₁-C₃₀ heterocyclic group” as used herein refers to a monocyclic group or a polycyclic group, and, according to its chemical structure, a monovalent, divalent, trivalent, tetravalent, pentavalent, or hexavalent group.

[0276] The term “nitrogen atom-containing C₁-C₃₀ heterocyclic group” as used herein refers to a saturated or

unsaturated cyclic group having at least one N as a ring-forming atom and 1 to 30 carbon atoms. The term “nitrogen atom-containing C₁-C₃₀ heterocyclic group” as used herein refers to a monocyclic group or a polycyclic group, and, according to its chemical structure, a monovalent, divalent, trivalent, tetravalent, pentavalent, or hexavalent group.

[0277] At least one substituent of the substituted C₅-C₃₀ carbocyclic group, the substituted C₁-C₃₀ heterocyclic group, the substituted C₁-C₆₀ alkyl group, the substituted C₂-C₆₀ alkenyl group, the substituted C₂-C₆₀ alkynyl group, the substituted C₁-C₆₀ alkoxy group, the substituted C₃-C₁₀ cycloalkyl group, the substituted C₁-C₁₀ heterocycloalkyl group, the substituted C₃-C₁₀ cycloalkenyl group, the substituted C₁-C₁₀ heterocycloalkenyl group, the substituted C₆-C₆₀ aryl group, the substituted C₆-C₆₀ aryloxy group, the substituted C₆-C₆₀ arylthio group, the substituted C₁-C₆₀ heteroaryl group, substituted monovalent non-aromatic condensed polycyclic group, and the substituted monovalent non-aromatic condensed heteropolycyclic group may be selected from:

[0278] deuterium, —F, —Cl, —Br, —I, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₆₀ alkyl group, a C₂-C₆₀ alkenyl group, a C₂-C₆₀ alkynyl group, and a C₁-C₆₀ alkoxy group; a C₁-C₆₀ alkyl group, a C₂-C₆₀ alkenyl group, a C₂-C₆₀ alkynyl group, and a C₁-C₆₀ alkoxy group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₁-C₆₀ heteroaryl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, —N(Q₁₁)(Q₁₂), —Si(Q₁₃)(Q₁₄)(Q₁₅), —B(Q₁₆)(Q₁₇), and —P(=O)(Q₁₈)(Q₁₉);

[0279] a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₁-C₆₀ heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group;

[0280] a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₁-C₆₀ heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₆₀ alkyl group, a C₂-C₆₀ alkenyl group, a C₂-C₆₀ alkynyl group,

a C₁-C₆₀ alkoxy group, a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₁-C₆₀ heteroaryl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, —N(Q₂₁)(Q₂₂), —Si(Q₂₃)(Q₂₄)(Q₂₅), —B(Q₂₆)(Q₂₇), and —P(=O)(Q₂₈)(Q₂₉); and

[0281] —N(Q₃₁)(Q₃₂), —Si(Q₃₃)(Q₃₄)(Q₃₅), —B(Q₃₆)(Q₃₇), and —P(=O)(Q₃₈)(Q₃₉),


[0282] wherein Q₁ to Q₉, Q₁₁ to Q₁₉, Q₂₁ to Q₂₉, and Q₃₁ to Q₃₉ may each independently be selected from hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₆₀ alkyl group, a C₂-C₆₀ alkenyl group, a C₂-C₆₀ alkynyl group, a C₁-C₆₀ alkoxy group, a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₆-C₆₀ aryl group substituted with at least one selected from a C₁-C₆₀ alkyl group, and a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₁-C₆₀ heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group.

[0283] Hereinafter, a compound and an organic light-emitting device according to embodiments are described in detail with reference to Synthesis Example and Examples. However, the organic light-emitting device is not limited thereto. The wording “‘B’ was used instead of ‘A’” used in describing Synthesis Examples means that a molar equivalent of ‘A’ was identical to a molar equivalent of ‘B’.

EXAMPLES

Synthesis Example 1: Synthesis of Compound 8

[0284] (1) Synthesis of Intermediate 8(1)



[0285] 2.24 grams (g) (0.0085 moles, mol) of 2-bromo-4-(2,6-dimethylphenyl)pyridine, 1 g (0.0085 mol) of 6-azaindole, 0.33 g (0.0017 mol) of copper iodide, 1.11 g (0.0034 mol) of cesium carbonate, and 0.51 g (0.0051 mol) of 1,2-diaminobenzene were added to 20 milliliters (ml) of dimethyl sulfoxide, and the mixed solution was heated at a temperature of 120° C. for 12 hours in a nitrogen atmosphere. After the termination of the reaction, the reaction mixture was cooled, and then, diluted with chloromethane and water. The organic layer obtained therefrom was dried by using MgSO₄, and concentrated. The resultant crude compound was purified by column chromatography (dichloromethane:ethyl acetate=9:1 (volume:volume)) to obtain 1.54 g (yield: 54%) of Intermediate 8(1). The obtained compound was identified by ¹H-NMR and LC-MASS.


[0286] ¹H-NMR, (600 MHz, CD₂Cl₂): δ (ppm) 6.76 (d, 1H, J=7.44 Hz), 7.10 (m, 1H), 7.18 (m, 2H), 7.26 (m, 1H), 7.38 (s, 1H), 7.64 (s, 1H), 7.39 (s, 1H), 8.44 (s, 1H), 8.67 (d, 1H, J=6.66 Hz), 9.84 (s, 1H).

[0287] LC-MASS (MH⁺–300.139).


[0288] ¹H-NMR, (600 MHz, CD₂Cl₂): δ (ppm) 6.76 (d, 1H, J=7.44 Hz), 7.10 (m, 1H), 7.18 (m, 2H), 7.26 (m, 1H), 7.38 (s, 1H), 7.64 (s, 1H), 7.39 (s, 1H), 8.44 (s, 1H), 8.67 (d, 1H, J=6.66 Hz), 9.84 (s, 1H).

[0289] LC-MASS (MH⁺–300.139)


[0290] (2) Synthesis of Intermediate 8(2)



[0291] 6.58 g (0.02 mol) of Intermediate 8(1), 3 g (0.008 mol) of iridium chloride, and 40 ml of a mixture of ethoxy-ethanol:water (4:1=volume:volume) were heated at a temperature of 115° C. overnight. After the termination of the reaction, the mixture was cooled at room temperature, and then, diluted with 30 ml of water. The yellow precipitate was filtered therefrom, washed by using water and ethanol, and then, dried under vacuum to obtain Intermediate 8(2). Intermediate 8(2) was used in the next step without further purification.

[0292] (3) Synthesis of Intermediate 8(3)

[0293] 3.54 g (0.001 g) of Intermediate 8(2) and 0.56 g (0.0022 mol) of silver triflate were dissolved in 15 ml of iso-propyl alcohol and 35 ml of dichloromethane. The mixture was stirred for 5 hours, filtered by using Celite, and washed by using dichloromethane. The solvent was evaporated therefrom under vacuum to obtain Intermediate 8(3). Intermediate 8(3) was used in the next step without a further purification process performed thereon.

[0294] (4) Synthesis of Compound 8


[0295] 1.54 g (0.0051 mol) of Intermediate 8(1) and 3 g (0.0031 mol) of Intermediate 8(3) were dissolved in 15 ml of 1,2-propanediol, and the mixed solution was heated at a temperature of 180° C. overnight. After the completion of

the reaction, the reaction mixture was diluted with dichloromethane, and purified by column chromatography (dichloromethane::ethyl acetate=2:1 (volume:volume)) to obtain 0.73 g (yield=21%) of Compound 8. The obtained compound was identified by MALDI and ¹H-NMR, and the results are shown in FIGS. 2 and 3.

[0296] ¹H-NMR, (600 MHz, DMF-d₇): δ (ppm) 6.00 (s, 1H), 6.88 (d, 1H, J=9.36 Hz), 7.06 (d, 1H, J=4 Hz), 7.12 (d, 1H, J=9.42 Hz), 7.20-7.36, (m, 6H), 7.59 (m, 1H), 7.68 (t, 1H, J=9.45 Hz), 7.85 (d, 1H, J=7.26), 8.02 (m, 6H), 8.23 (s, 1H), 8.45 (d, 1H, J=7.32), 8.60 (d, 1H, J=6 Hz), 8.76 (d, 1H, J=4.14), 10.04 (s, 1H).

Evaluation Example 1: Evaluation of Photoluminescence (PL) Spectrum

[0297] As the PL spectra of Compound 8 and Compound A were evaluated, photoluminescent properties of each compound were also evaluated. In detail, Compound 8 was diluted with CH₂Cl₂ to a concentration of about 10 millimolar (mM), and an ISC PC1 spectrofluorometer equipped with a xenon light source was used to measure a PL spectrum of Compound 8 at room temperature. The same process was repeated on Compound A to measure a PL thereof. A maximum wavelength in the PL spectrum of Compound 8 is summarized in Table 1 and FIG. 4:



C₁-C₆₀ alkoxy group, a substituted or unsubstituted C₃-C₁₀ cycloalkyl group, a substituted or unsubstituted heterocycloalkyl group, a substituted or unsubstituted C₃-C₁₀ cycloalkenyl group, a substituted or unsubstituted heterocycloalkenyl group, a substituted or unsubstituted C₆-C₆₀ aryl group, a substituted or unsubstituted C₆-C₆₀ aryloxy group, a substituted or unsubstituted C₆-C₆₀ arylthio group, a substituted or unsubstituted C₁-C₆₀ heteroaryl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group, —N(Q₁)(Q₂), —Si(Q₃)(Q₄)(Q₅), —B(Q₆)(Q₇), and —P(=O)(Q₈)(Q₉),

R₁₁ to R₁₃ are optionally linked to form a ring,

two, three, or four of a plurality of R₁₁ to R₁₃ that are adjacent to each other are optionally linked to form a quadridentate, hexadentate, or octadentate ligand,

b12 and b13 are each independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10,

n11 is selected from 1, 2, 3, and 4,

n12 is selected from 0, 1, 2, and 3,

L₁₂ is selected from a bidentate ligand,

Q₁ to Q₉ were each independently selected from hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₆₀ alkyl group, a C₁-C₆₀ alkyl group substituted with at least one selected from deuterium, a C₁-C₆₀ alkyl group, and a C₆-C₆₀ aryl group, a C₂-C₆₀ alkenyl group, a C₂-C₆₀ alkynyl group, a C₁-C₆₀ alkoxy group, a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₆-C₆₀ aryl group substituted with at least one selected from deuterium, a C₁-C₆₀ alkyl group, and a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₁-C₆₀ heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group.

2. The organometallic compound of claim 1, wherein the M₁₁ is selected from platinum (Pt), palladium (Pd), copper (Cu), silver (Ag), gold (Au), rhodium (Rh), iridium (Ir), ruthenium (Ru), osmium (Os), titanium (Ti), zirconium (Zr), hafnium (Hf), rhenium (Re), europium (Eu), terbium (Tb), thulium (Tm), and lead (Pb).


3. The organometallic compound of claim 1, wherein A₁₁ and A₁₂ are each independently selected from an indole group, a carbazole group, an indenopyridine group, an indolopyridine group, a benzofuopyridine group, a benzothienopyridine group, a benzosilolopyridine group, an indeno pyrimidine group, an indolopyrimidine group, a benzofuopyrimidine group, a benzothienopyrimidine group, a benzosilolopyrimidine group, a dihydropyridine group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, a quinoline group, an isoquinoline group, a quinoxaline group, a quinazoline group, a phenanthroline group, a pyrrole group, a pyrazole group, an imidazole group, a 2,3-dihydroimidazole group, a triazole group, a 2,3-dihydrotriazole group, an oxazole group, an iso-oxazole group, a thiazole group, an isothiazole group, an oxadiazole group, a thiadiazole group,

a benzopyrazole group, a benzimidazole group, a 2,3-dihydrobenzimidazole group, an imidazopyridine group, a 2,3-dihydroimidazopyridine group, an imidazopyrimidine group, a 2,3-dihydroimidazopyrimidine group, an imidazopyrazine group, a 2,3-dihydroimidazopyrazine group, a benzoxazole group, a benzothiazole group, a benzooxadiazole group, a benzothiadiazole group, a 5,6,7,8-tetrahydroisoquinoline group, and a 5,6,7,8-tetrahydroquinoline group.


4. The organometallic compound of claim 1, wherein A₁₁ and A₁₂ are each independently selected from an indenopyridine group, an indolopyridine group, a benzofuopyridine group, a benzothienopyridine group, a benzosilolopyridine group, an indeno pyrimidine group, an indolopyrimidine group, a benzofuopyrimidine group, a benzothienopyrimidine group, a benzosilolopyrimidine group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, a quinoline group, an isoquinoline group, a quinoxaline group, a quinazoline group, a phenanthroline group, an imidazopyridine group, an imidazopyrimidine group, and an imidazopyrazine group.

5. The organometallic compound of claim 1, wherein X₁₁ and X₁₂ are each independently C.


6. The organometallic compound of claim 1, wherein a partial structure represented by




(wherein * and *' each indicate a binding site to a neighboring atom) is represented by one of Formulae 2-1 to 2-12:



2-1




2-2




2-3


-continued




2-4




2-5




2-6




2-7



2-8




2-9




2-10

-continued



2-11




2-12


wherein, in Formulae 2-1 to 2-12,

R₁₁ is the same as described in Formula 1,R₂₁ to R₂₄ are each independently the same as described in connection with R₁₂ in Formula 1, andand *₁ each indicate a binding site to a neighboring atom.


7. The organometallic compound of claim 1, wherein a moiety represented by




is represented by one of Formulae 3-1 to 3-5:



3-1




3-2




3-3

-continued



3-4



3-5

wherein, in Formulae 3-1 to 3-5,

R_{31} to R_{34} are each independently the same as described in connection with R_{13} in Formula 1, and

and * each indicate a binding site to a neighboring atom.

8. The organometallic compound of claim 1, wherein R_{11} to R_{13} are each independently selected from:

hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, —SF₅, C₁-C₂₀ alkyl group, and a C₁-C₂₀ alkoxy group;

a C₁-C₂₀ alkyl group and a C₁-C₂₀ alkoxy group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₁₀ alkyl group, a cyclopentyl group, a cyclopentyl group substituted with deuterium, a cyclohexyl group, a cyclohexyl group substituted with deuterium, a cycloheptyl group, a cycloheptyl group substituted with deuterium, a cyclooctyl group, a cyclooctyl group substituted with deuterium, a bicyclo [2.2.1]heptanyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a pyridinyl group, and a pyrimidinyl group;

a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, a bicyclo[2.2.1]heptanyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a

quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a dibenzosilolyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, and an imidazopyrimidinyl group;

a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, a bicyclo[2.2.1]heptanyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a

cinnoliny group, a carbazolyl group, a phenanthroliny group, a benzimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a dibenzosilolyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, and $-\text{Si}(\text{Q}_{33})(\text{Q}_{34})(\text{Q}_{35})$; and $-\text{N}(\text{Q}_1)(\text{Q}_2)$, $-\text{Si}(\text{Q}_3)(\text{Q}_4)(\text{Q}_5)$, $-\text{B}(\text{Q}_6)(\text{Q}_7)$, and $-\text{P}(=\text{O})(\text{Q}_8)(\text{Q}_9)$, and

Q_1 to Q_9 and Q_{33} to Q_{35} are each independently selected from:

$-\text{CH}_3$, $-\text{CD}_3$, $-\text{CD}_2\text{H}$, $-\text{CDH}_2$, $-\text{CH}_2\text{CH}_3$, $-\text{CH}_2\text{CD}_3$, $-\text{CH}_2\text{CD}_2\text{H}$, $-\text{CH}_2\text{CDH}_2$, $-\text{CHDCH}_3$, $-\text{CHDCD}_2\text{H}$, $-\text{CHDCDH}_2$, $-\text{CHDCH}_3$, $-\text{CD}_2\text{CD}_3$, $-\text{CD}_2\text{CD}_2\text{H}$, and $-\text{CD}_2\text{CDH}_2$;

an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, a sec-pentyl group, a tert-pentyl group, a phenyl group, and a naphthyl group; and

an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, a sec-pentyl group, a tert-pentyl group, a phenyl group, and a naphthyl group, each substituted with at least one selected from deuterium, a C_1 - C_{10} alkyl group, and a phenyl group.

9. The organometallic compound of claim 1, wherein R_{11} to R_{13} are each independently selected from:

hydrogen, deuterium, $-\text{F}$, a cyano group, a nitro group, $-\text{SF}_5$, a methyl group, an ethyl group, an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, a sec-pentyl group, a tert-pentyl group, an n-hexyl group, an iso-hexyl group, a sec-hexyl group, a tert-hexyl group, an n-heptyl group, an iso-heptyl group, a sec-heptyl group, a tert-heptyl group, an n-octyl group, an iso-octyl group, a sec-octyl group, a tert-octyl group, an n-nonyl group, an iso-nonyl group, a sec-nonyl group, a tert-nonyl group, an n-decyl group, an iso-decyl group, a sec-decyl group, a tert-decyl group, a methoxy group, an ethoxy group, a propoxy group, a butoxy group, a pentoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, a bicyclo[2.2.1]heptanyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, a fluorenyl group, a carbazolyl group, a dibenzofuranyl group, a dibenzothiophenyl group, and a dibenzosilolyl group;

a methyl group, an ethyl group, an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, a sec-pentyl group, a tert-pentyl group, an n-hexyl group, an iso-hexyl group, a sec-hexyl group, a tert-hexyl group, an n-heptyl group, an iso-heptyl group, a sec-heptyl group, a tert-heptyl group, an n-octyl group, an iso-octyl group, a sec-octyl group, a tert-octyl group, an n-nonyl group, an iso-

nonyl group, a sec-nonyl group, a tert-nonyl group, an n-decyl group, an iso-decyl group, a sec-decyl group, a tert-decyl group, a methoxy group, an ethoxy group, a propoxy group, a butoxy group, a pentoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, a bicyclo[2.2.1]heptanyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, a fluorenyl group, a carbazolyl group, a dibenzofuranyl group, a dibenzothiophenyl group, and a dibenzosilolyl group, each substituted with at least one selected from deuterium, $-\text{F}$, $-\text{CD}_3$, $-\text{CD}_2\text{H}$, $-\text{CDH}_2$, $-\text{CF}_3$, $-\text{CF}_2\text{H}$, $-\text{CFH}_2$, a cyano group, a nitro group, a C_1 - C_{10} alkyl group, a C_1 - C_{10} alkoxy group, a cyclopentyl group, a cyclopentyl group substituted with deuterium, a cyclohexyl group, a cyclohexyl group substituted with deuterium, a cycloheptyl group, a cycloheptyl group substituted with deuterium, a cyclooctyl group, a cyclooctyl group substituted with deuterium, a bicyclo[2.2.1]heptanyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, a fluorenyl group, a carbazolyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a dibenzosilolyl group, and $-\text{Si}(\text{Q}_{33})(\text{Q}_{34})(\text{Q}_{35})$; and

$-\text{N}(\text{Q}_1)(\text{Q}_2)$, $-\text{Si}(\text{Q}_3)(\text{Q}_4)(\text{Q}_5)$, $-\text{B}(\text{Q}_6)(\text{Q}_7)$, and $-\text{P}(=\text{O})(\text{Q}_8)(\text{Q}_9)$, and


Q_1 to Q_9 and Q_{33} to Q_{35} are each independently selected from:

$-\text{CH}_3$, $-\text{CD}_3$, $-\text{CD}_2\text{H}$, $-\text{CDH}_2$, $-\text{CH}_2\text{CH}_3$, $-\text{CH}_2\text{CD}_3$, $-\text{CH}_2\text{CD}_2\text{H}$, $-\text{CH}_2\text{CDH}_2$, $-\text{CHDCH}_3$, $-\text{CHDCD}_2\text{H}$, $-\text{CHDCDH}_2$, $-\text{CHDCH}_3$, $-\text{CD}_2\text{CD}_3$, $-\text{CD}_2\text{CD}_2\text{H}$, and $-\text{CD}_2\text{CDH}_2$;


an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, a sec-pentyl group, a tert-pentyl group, a phenyl group, and a naphthyl group; and

an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, a sec-pentyl group, a tert-pentyl group, a phenyl group, and a naphthyl group, each substituted with at least one selected from deuterium, a C_1 - C_{10} alkyl group, and a phenyl group.































10. The organometallic compound of claim 1, wherein R_{11} to R_{13} are each independently selected from hydrogen, deuterium, $-\text{F}$, a cyano group, a nitro group, $-\text{SF}_5$, $-\text{CH}_3$, $-\text{CD}_3$, $-\text{CD}_2\text{H}$, $-\text{CDH}_2$, $-\text{CF}_3$, $-\text{CF}_2\text{H}$, $-\text{CFH}_2$, groups represented by Formulae 9-1 to 9-21, groups represented by Formulae 10-1 to 10-253, $-\text{N}(\text{Q}_1)(\text{Q}_2)$, $-\text{Si}(\text{Q}_3)(\text{Q}_4)(\text{Q}_5)$, $-\text{B}(\text{Q}_6)(\text{Q}_7)$, and $-\text{P}(=\text{O})(\text{Q}_8)(\text{Q}_9)$:























9-1




9-2


-continued	9-3	-continued	9-20
			
	9-4		9-21
	9-5		
	9-6		10-1
	9-7		10-2
	9-8		10-3
	9-9		10-4
	9-10		
	9-11		10-5
	9-12		10-6
	9-13		
	9-14		10-7
	9-15		10-8
	9-16		10-9
	9-17		10-10
	9-18		
	9-19		10-11

-continued		-continued	
	10-12		10-22
	10-13		
			10-23
	10-14		10-24
			
	10-15		10-25
			10-26
	10-16		
			10-27
	10-17		
			10-28
	10-18		
			10-29
	10-19		
			10-30
	10-20		
			10-31
	10-21		


-continued




10-32




10-33




10-34




10-35




10-36




10-37




10-38




10-39



10-40




10-41




10-42


-continued




10-43




10-44




10-45




10-46




10-47




10-48




10-49




10-50




10-51



10-52




10-53
10-54
10-55
10-56
10-57
10-58
10-59
10-60
10-61
10-62
10-63




10-64
10-65
10-66
10-67
10-68
10-69
10-70
10-71
10-72
10-73


-continued




10-74




10-75




10-76




10-77




10-78




10-79




10-80




10-81



10-82




10-83




10-84


-continued




10-85




10-86




10-87




10-88




10-89




10-90



10-91




10-92




10-93


-continued




-continued




-continued




10-112




10-113




10-114




10-115




10-116




10-117



10-118




10-119




10-120


-continued




10-121




10-122




10-123




10-124




10-125




10-126



10-127




10-128




10-129


-continued




10-130




10-131




10-132




10-133




10-134




10-135




10-136



10-137




10-138




10-139


-continued




10-140




10-141




10-142




10-143




10-144




10-145




10-146




10-147





10-148




10-149




10-150




-continued




-continued




-continued




10-189




10-190




10-191




10-192




10-193



10-194




10-195




10-196


-continued




10-197




10-198




10-199




10-200




10-201




10-202



10-203




10-204




10-205


-continued




-continued




-continued




10-222




10-223




10-224




10-225




10-226



10-227




10-228




10-229


-continued




10-230




10-231




10-232




10-233



10-234




10-235




10-236


-continued




10-237




10-238




10-239




10-240



10-241




10-242




10-243


-continued



10-244



10-245



10-246

wherein, in Formulae 9-1 to 9-21 and 10-1 to 10-253,

Q_1 to Q_9 are each independently selected from:

—CH₃, —CD₃, —CD₂H, —CDH₂, —CH₂CH₃,
—CH₂CD₃, —CH₂CD₂H, —CH₂CDH₂, —CHDCD₃,
—CHDCD₂H, —CHDCDH₂, —CHDCD₃,
—CD₂CD₃, —CD₂CD₂H, and —CD₂CDH₂;

an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, a sec-pentyl group, a tert-pentyl group, a phenyl group, and a naphthyl group; and

an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, a sec-pentyl group, a tert-pentyl group, a phenyl group, and a naphthyl group, each substituted with at least one selected from deuterium, a C₁-C₁₀ alkyl group, and a phenyl group,

* indicates a binding site to a neighboring atom,

i-Pr indicates an iso-propyl group,

t-Bu indicates t-butyl group,

Ph indicates a phenyl group,


1-Nph indicates a 1-naphthyl group and 2-Nph indicates a 2-naphthyl group,

2-Pyr indicates a 2-pyridyl group, 3-Pyr indicates a 3-pyridyl group, and 4-Pyr indicates a 4-pyridyl group, and

TMS indicates a trimethylsilyl group.

11. The organometallic compound of claim 1, wherein M_{11} is Ir, n11 is selected from 1, 2, and 3, and n12 is selected from 0, 1, and 2.

12. The organometallic compound of claim 1, wherein L_{12} is a ligand represented by one of Formulae 7-1 to 7-7:



wherein, in Formulae 7-1 to 7-7,

A_{71} and A_{72} are each independently selected from a C_5 - C_{20} carbocyclic group and a C_1 - C_{20} heterocyclic group,

X_{71} and X_{72} are each independently selected from C and N,

X_{78} is O, S, or N(Q_{79}),

X_{29} is O, S, or N(Q_{79}),

Y_{71} and Y_{72} are each independently selected from a single bond, a double bond, a substituted or unsubstituted C_1 - C_5 alkenylene group, a substituted or unsubstituted

C_2 - C_5 alkenylene group, and a substituted or unsubstituted C_6 - C_{10} arylene group,

Z_{71} and Z_{72} are each independently selected from N, O, N(R_{75}), P(R_{75})(R_{76}), and As(R_{75})(R_{76}),

Z_{74} is selected from CO and CH_2 ,

R_{71} , R_{72} , R_{75} to R_{80} , and Q_{73} to Q_{79} are each independently selected from hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a substituted or unsubstituted C_1 - C_{60} alkyl group, a substituted or unsubstituted C_2 - C_{60} alkenyl group, a substituted or unsubstituted C_2 - C_{60} alkynyl group, a substituted or unsubstituted C_1 - C_{60} alkoxy group, a substituted or unsubstituted C_3 - C_{10} cycloalkyl group, a substituted or unsubstituted C_1 - C_{10} heterocycloalkyl group, a substituted or unsubstituted C_3 - C_{10} cycloalkenyl group, a substituted or unsubstituted C_1 - C_{10} heterocycloalkenyl group, a substituted or unsubstituted C_6 - C_{60} aryl group, a substituted or unsubstituted C_6 - C_{60} aryloxy group, a substituted or unsubstituted C_6 - C_{60} arylthio group, a substituted or unsubstituted C_1 - C_{60} heteroaryl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, and a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group,

R_{71} and R_{72} are optionally linked to form a ring,

R_{77} and R_{78} are optionally linked to form a ring,


R_{78} and R_{79} are optionally linked to form a ring,

R_{79} and R_{80} are optionally linked to form a ring,


b_{71} and b_{72} are each independently selected from 1, 2, 3, 4, 5, and 6, and

* and *' each indicate a binding site to a neighboring atom.


13. The organometallic compound of claim 1, wherein L_{12} is a ligand represented by one of Formulae 8-1 to 8-32:




-continued




8-4




8-5




8-6



8-7




8-8




8-9


-continued




8-10




8-11




8-12



8-13




8-14




8-15


-continued




8-16




8-17




8-18



8-19




8-20




8-21


-continued




8-22




8-23




8-24



8-25




8-26




8-27

-continued




8-28


-continued




5-2




8-29




5-3




8-30




5-4




8-31




5-5




8-32




5-6




5-1




5-7




5-12




5-8




5-13




5-9




5-14




5-10



5-15




5-11




5-16

-continued




5-17


-continued




5-22




5-18




5-23




5-19




5-24




5-20



5-25




5-21




5-26

-continued




5-27


-continued




5-32




5-28




5-33




5-29




5-34




5-30



5-35




5-31




5-36

-continued




5-37


-continued




5-42




5-38




5-43




5-39




5-44




5-40




5-45



5-41




5-46




5-47


-continued




5-48




5-49




5-50



5-51




5-52




5-53


-continued




5-54




5-55




5-56



5-57




5-58




5-59


-continued




5-60




5-61




5-62



5-63




5-64




5-65


-continued




5-66




5-67



5-68








5-69




5-70

-continued




-continued


5-86




5-87




5-88




5-89



5-90




-continued




5-91


-continued




5-96




5-92




5-97




5-93




5-98




5-94



5-99




5-95




5-100

-continued




5-101


-continued




5-106




5-102




5-107




5-103




5-108




5-104



5-109




5-105




5-110

-continued



5-111

-continued



5-116

wherein, in Formulae 5-1 to 5-116 and 8-1 to 8-32,

R₅₁ to R₅₃ are each independently selected from:

hydrogen, —F, a cyano group, a nitro group, a methyl group, an ethyl group, a propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, a sec-pentyl group, a tert-pentyl group, an n-hexyl group, an iso-hexyl group, a sec-hexyl group, a tert-hexyl group, an n-heptyl group, an iso-heptyl group, a sec-heptyl group, a tert-heptyl group, an n-octyl group, an iso-octyl group, a sec-octyl group, a tert-octyl group, an n-nonyl group, an iso-nonyl group, a sec-nonyl group, a tert-nonyl group, an n-decanyl group, an iso-decanyl group, a sec-decanyl group, a tert-decanyl group, a methoxy group, an ethoxy group, a propoxy group, a butoxy group, a pentoxy group, a phenyl group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, a triazinyl group, a dibenzofuranyl group, and a dibenzothiophenyl group; and

a methyl group, an ethyl group, a propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an iso-pentyl group, a sec-pentyl group, a tert-pentyl group, an n-hexyl group, an iso-hexyl group, a sec-hexyl group, a tert-hexyl group, an n-heptyl group, an iso-heptyl group, a sec-heptyl group, a tert-heptyl group, an n-octyl group, an iso-octyl group, a sec-octyl group, a tert-octyl group, an n-nonyl group, an iso-nonyl group, a sec-nonyl group, a tert-nonyl group, an n-decanyl group, an iso-decanyl group, a sec-decanyl group, a tert-decanyl group, a methoxy group, an ethoxy group, a propoxy group, a butoxy group, a pentoxy group, a phenyl group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, a triazinyl group, a dibenzofuranyl group, and a dibenzothiophenyl group, each substituted with at least one selected from —F, a cyano group, and a nitro group,

b51 and b54 are each independently selected from 1 and 2,

b53 and b55 are each independently selected from 1, 2, and 3,


b52 is selected from 1, 2, 3, and 4,

Ph indicates a phenyl group,


Ph-d5 indicates a phenyl group of which all hydrogen atoms are substituted with deuterium, and

* and *' each indicate a binding site to a neighboring atom.


14. The organometallic compound of claim 1, wherein the organometallic compound of Formula 1 is represented by one of Formulae 1-1 to 1-4:




5-112







5-113



5-114



5-115



wherein, in Formulae 1-1 to 1-4,
 M_{11} , R_{11} , n_{11} , n_{12} , and L_{12} are the same as described in Formula 1,

R_{21} to R_{24} are each independently the same as described in connection with R_{12} in Formula 1, and
 R_{31} to R_{34} are each independently the same as described in connection with R_{13} in Formula 1.

15. The organometallic compound of claim 14, wherein R_{11} , R_{21} to R_{24} , and R_{31} to R_{34} are each independently selected from:

hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, —SF₅, C₁-C₂₀ alkyl group, and a C₁-C₂₀ alkoxy group;

a C₁-C₂₀ alkyl group and a C₁-C₂₀ alkoxy group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₁₀ alkyl group, a cyclopentyl group, a cyclopentyl group substituted with deuterium, a cyclohexyl group, a cyclohexyl group substituted with deuterium, a cycloheptyl group, a cycloheptyl group substituted with deuterium, a cyclooctyl group, a cyclooctyl group substituted with deuterium, a bicyclo [2.2.1]heptanyl group), an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a pyridinyl group, and a pyrimidinyl group;

a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, a bicyclo[2.2.1]heptanyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazoyl group, a phenanthrolinyl group, a benzimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a dibenzosilolyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, and an imidazopyrimidinyl group;

a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, a bicyclo[2.2.1]heptanyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl

group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a dibenzosilolyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, and an imidazopyrimidinyl group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₂₀ alkyl group, a C₁-C₂₀ alkoxy group, a cyclopentyl group, a cyclopentyl group substituted with deuterium, a cyclohexyl group, a cyclohexyl group substituted with deuterium, a cycloheptyl group, a cycloheptyl group substituted with deuterium, a cyclooctyl group, a cyclooctyl group substituted with deuterium, a bicyclo [2.2.1]heptanyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a dibenzosilolyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, and —Si(Q₃₃)(Q₃₄)(Q₃₅); and

—N(Q₁)(Q₂), —Si(Q₃)(Q₄)(Q₅), —B(Q₆)(Q₇), and —P(=O)(Q₈)(Q₉), and




Q₁ to Q₅ and Q₃₃ to Q₃₅ are each independently selected from:

—CH₃, —CD₃, —CD₂H, —CDH₂, —CH₂CH₃, —CH₂CD₃, —CH₂CD₂H, —CH₂CDH₂, —CHDCD₃, —CHDCD₂H, —CHDCD₂H, —CHDCD₃, —CD₂CD₃, —CD₂CD₂H, and —CD₂CDH₂;


an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, a sec-pentyl group, a tert-pentyl group, a phenyl group, and a naphthyl group; and

an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, a sec-pentyl group, a tert-pentyl group, a phenyl group, and a naphthyl group, each substituted with at least one selected from deuterium, a C₁-C₁₀ alkyl group, and a phenyl group.


16. The organometallic compound of claim 1, wherein the organometallic compound of Formula 1 is selected from Compounds 1 to 8:



-continued



-continued



17. The organometallic compound of claim 1, wherein a maximum emission wavelength of the organometallic compound is in a range of about 440 nanometers or more to less than about 500 nanometers.

18. An organic light-emitting device comprising:

a first electrode;

a second electrode; and

an organic layer disposed between the first electrode and second electrode, and

wherein the organic layer comprises an emission layer, and

wherein the organic layer comprises at least one organometallic compound of claim 1.

19. The organic light-emitting device of claim 18, wherein the emission layer comprises the organometallic compound.

20. The organic light-emitting device of claim 19, wherein the emission layer further comprises a host, wherein an amount of the host is greater than an amount of the organometallic compound.

* * * * *

专利名称(译)	有机金属化合物和包括其的有机发光器件		
公开(公告)号	US20190067599A1	公开(公告)日	2019-02-28
申请号	US16/057929	申请日	2018-08-08
[标]申请(专利权)人(译)	三星电子株式会社		
申请(专利权)人(译)	SAMSUNG ELECTRONICS CO. , LTD. 三星SDI CO. , LTD.		
当前申请(专利权)人(译)	SAMSUNG ELECTRONICS CO. , LTD. 三星SDI CO. , LTD.		
[标]发明人	KRAVCHUK DMITRY KIM WOOK KIM JUHYUN NOH CHANGHO PARK SANGHO ISHIBE SATOKO KANG SEOKHO YOO JIHO LEE DONGSEON LEE HASUP CHWAE JUN		
发明人	KRAVCHUK, DMITRY KIM, WOOK KIM, JUHYUN NOH, CHANGHO PARK, SANGHO ISHIBE, SATOKO KANG, SEOKHO KIM, INKOO YOO, JIHO LEE, DONGSEON LEE, HASUP CHWAE, JUN		
IPC分类号	H01L51/00 C07F15/00		
CPC分类号	H01L51/0085 C07F15/0033 H01L51/5016		
优先权	1020170111043 2017-08-31 KR		
外部链接	Espacenet USPTO		

摘要(译)

由式1表示的有机金属化合物：其中，在公式1中，组和变量与规范中描述的相同。

